- Need Technical Assistance? dcan2022@getvfairs.io
Jonathan is a bioengineer with expertise in biofabrication and stem cell biology. He has a Bachelor’s degree in Chemical Engineering from Université Laval, and a Master’s degree in Life Science Engineering from EPFL, where he developed novel technologies for organoid bioprinting. He is currently doing his PhD in the laboratory of Prof. Corinne Hoesli at McGill University, where he works on vascularization of macroencapsulation devices and stem cell derived islets.
Participants should be aware of the following financial/non-financial relationships:
Valeria E. Rac MD, PhD: Nothing to Disclose
Jonathan Brassard MSc: N/A - Individual: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Presenting at:
Stem cell therapies for diabetes: What’s new and what’s on the horizon? - 10:15 AM, November 11th
Dr. Rac is a full-time Scientist and Health Technology Assessment Lead with the Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre at the Toronto General Hospital Research Institute (TGHRI), University Health Network. She is also the Director of the Program for Health System and Technology Evaluation, TGHRI. She is an Associate Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, where she is a Co-Chair of the Equity, Diversity and Inclusion Committee. Dr. Rac is a Co-Lead of two research programs with the CIHR SPOR Diabetes Action Canada Network: Knowledge Mobilization, Implementation and Evaluation Program and Diabetic Retinopathy Screening Program. Dr. Rac’s expertise is in health technology assessment, evaluation and health services research. Her program is focused on program evaluations and complex interventions in chronic disease management, working closely with patients and their family members, community partners, innovators, researchers and government/policy-makers. Using a variety of evaluative approaches to assess our health-care system, Dr. Rac and her team provide rapid real-time feedback to all involved stakeholders that contribute to the establishment of a learning health-care system. They generate rigorous evidence and provide decision support to implement innovative, system-disruptive technologies that empower patients, deliver the best outcomes, and create high-performing, cost-effective health-care systems. Dr. Rac is leading a national team of stakeholders awarded the CIHR and Diabetes Canada Team Grant "Preventing Vision Loss from Diabetic Retinopathy - Guiding Primary Care Diabetic Retinopathy Screening in Canada Through the Use of Provincial Healthcare Administrative Data."
Participants should be aware of the following financial/non-financial relationships:
Valeria E. Rac MD, PhD: Nothing to Disclose
Presenting at:
Role of Patient-Oriented Research in Developing New Models of Care - 10:15 AM, November 10th
Marisa is a Cree Woman from the Saddle Lake Cree Nation in the Treaty 6 Territory in Alberta, Canada. Her background is in nutrition and food science, and she is currently a Co-Chair for the National Indigenous Diabetes Association. She is an advocate for exercise and diabetes for Indigenous peoples and their communities.
Participants should be aware of the following financial/non-financial relationships:
Marisa Cardinal: Nothing to Disclose
Presenting at:
Personal Journey with Diabetes - 2:25 PM, November 10th
Dr. Doumouras is a staff surgeon in Minimally Invasive and Bariatric Surgery at St. Joseph's Healthcare and an Assistant Professor at McMaster University. He completed his Clinical Fellowship in Bariatric and Minimally Invasive Surgery at St. Joseph's Healthcare and his General Surgery training at McMaster University. He received his MD degree from Queen's University. During residency, Dr. Doumouras was awarded the Juravinski Fellowship from the McMaster Department of Surgery, as well as a Knox Fellowship from Harvard University to pursue graduate studies at Harvard where he obtained a Master of Public Health degree with a focus on Epidemiology and Biostatistics. As part of this degree, he completed a research practicum in surgical crisis simulation with Dr. Steven Yule and Dr. Douglas Smink at the STRATUS Center for Medical Simulation at Brigham and Women's Hospital. Dr. Doumouras has a passion for clinical research and brings a broad research background in bariatric, minimally invasive and endoscopic surgery highlighted by his CV and his appointment as an Adjunct Scientist at the Institute for Clinical Evaluative Sciences (IC/ES). He has published more than 50 papers principally relating to surgical outcomes, geographic access and costs, with a track record of being published in high impact journals, such as Annals of Surgery, JAMA Surgery and British Journal of Surgery. He has won several awards for presentations at national and international meetings, including first prize at the Resident and Fellow Research Competition at SAGES 2018.
Participants should be aware of the following financial/non-financial relationships:
Aristithes Doumouras MD, MPH, FRCSC: Nothing to Disclose
Presenting at:
Diabetes and Bariatric Surgery - 4:15 PM, November 11th
Dr. White completed training in Endocrinology and Metabolism at the University of British Columbia (UBC) in 2008, where he also completed undergraduate and Internal Medicine training. He is currently practicing within the St. Paul’s Hospital Division of Endocrinology. He is the current head of the Endocrine Research Society and Western Canada Insulin Pump Center, which is engaged in independent diabetes research and providing clinical care for patients using insulin pump technology. He has a special interest in medical education. He is Past-Chair of the Endocrinology and Metabolism undergraduate curriculum, and he has an ongoing involvement in postgraduate training in the UBC Division of Endocrinology. He has served on the Royal College of Physicians and Surgeons of Canada committee for Endocrinology and Metabolism. Also, he has previously engaged in the Planning Committee for the Diabetes Canada Clinical and Scientific Sessions meeting.
Participants should be aware of the following financial/non-financial relationships:
Adam White MD, FRCPC: Abbott Canada: Advisory Board (Ongoing); Abbott Canada: Speaker/Honoraria (Ongoing); Bayer: Advisory Board (Ongoing); Bayer: Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Janssen: Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing)
Presenting at:
Endocrinologists Diabetes Quiz Show (the rules are very similar to Jeopardy), hosted by Dr. Bruce Perkins - 11:45 AM, November 10th
Presenting at:
Endocrinologists Diabetes Quiz Show (the rules are very similar to Jeopardy), hosted by Dr. Bruce Perkins - 11:45 AM, November 10th
George Desjarlais is the youngest son in a family of 9 children. The family was raised in Northern Alberta in a traditional nehiyaw "Cree" way of life. Children were taught many aspects of life, including using wild plants to treat many common ailments and how to provide immunity. There have been many challenges to maintaining this way of life, and navigating modern society with traditional Cree knowledge has made for many learning experiences. Participants will learn about various plant species and hear stories related to his life
Presenting at:
Traditional Plant Knowledge - 10:15 AM, November 10th
Dr. Currie is an Associate Professor of Public Health in the Faculty of Health Sciences at the University of Lethbridge. As a social epidemiologist, her research is focused on the ways in which our social experiences, both positive and negative, get under the skin to shape our health, health-risk behaviour and stress biology.
Participants should be aware of the following financial/non-financial relationships:
Cheryl Currie PhD: Nothing to Disclose
Presenting at:
Stress and Diabetes - (Virtual)
Presenting at:
Beyond A1C: The Emerging Role of Time in Range - 6:45 PM, November 10th
Presenting at:
Inclusion, Diversity, Equity, Accessibility (IDEA) - Diabetes management in Immigrants to Canada - 4:15 PM, November 11th
Dr. Venos is an Endocrinologist at the University of Calgary. He received his Medical Degree and completed Internal Medicine training at the University of Toronto. He completed his Endocrinology fellowship at the University of Calgary. He is the clinical lead of the University of Calgary Multidisciplinary Familial Dyslipidemia Clinic, providing assessment and treatment for individuals and families across central and southern Alberta.
Presenting at:
CSEM 16th Annual Endocrine Residents’ Day Review Course - 8:00 AM, November 9th
Dr. Simon is a psychoanalyst, psychiatrist and Certified Diabetes Educator. He is an Assistant Professor of Psychiatry at the University of Toronto and a psychiatric consultant with the Leadership Centre for Diabetes at Mount Sinai Hospital in Toronto. For the past two decades, he has educated dietitians, diabetes educators, family doctors and medical specialists on effective motivational and psychological strategies for diabetes management, weight loss and lifestyle change.
Participants should be aware of the following financial/non-financial relationships:
Barry J. Simon MD, FRCP, CDE: Nothing to Disclose
Presenting at:
The Transformative Diabetes Conversation - 1:30 PM, November 9th
Presenting at:
Eureka Moments: How rtCGM has Changed our Practice - 6:00 PM, November 9th
Dr. Ratzki-Leewing is the lead Epidemiologist of the Diabetes Alliance Hypoglycemia Research Program at the Schulich School of Medicine & Dentistry (Western University) where she directs numerous national and international studies on the real-world clinical and behavioural epidemiology of diabetes-related hypoglycemia. Dr. Ratzki-Leewing's research focuses on the generation of patient-centered evidence relevant to the discovery of pragmatic and novel interventional targets for improved clinical decision-making and population health outcomes. Currently, she heads a nationwide (Canada) study on hypoglycemia incidence and management (InHypo-DM). She is also a Principal Investigator of one of the world’s largest prospective investigations of hypoglycemia risk stratification (iNPHORM, USA) and COVID-19 (iNPHORM COVID-19) in diabetes. Dr. Ratzki-Leewing was also the lead Epidemiologist for the multi-national TALK-HYPO study, a real-world investigation of hypoglycemia burden in family members of people with diabetes. She has published widely and presented on various hypoglycemia topics around the world. She is well-known for her ability to educate on epidemiology through an applied, primary care lens.
Participants should be aware of the following financial/non-financial relationships:
Alexandria Ratzki-Leewing PhD: Eli Lilly: Committee/Planning Member (Terminated); Eli Lilly: Speaker/Honoraria (Terminated); Novo Nordisk A/S: Consultant (Ongoing); Novo Nordisk A/S: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing); Sanofi: Grant/Research Support (Ongoing); Sanofi: Speaker/Honoraria (Ongoing)
Presenting at:
Hypoglycemia: Risk Considerations and New Strategies - 8:00 AM, Novermber 12th
Dr. Rabasa-Lhoret is Vice President (Clinical and Clinical Research) at the IRCM, medical doctor in the Endocrinology Division of the CHUM, and Professor of Medicine and Nutrition at the University of Montreal. He holds 3 diabetes research chairs and has received numerous awards and fellowships. His team holds large national and international funds. He has published over 350 manuscripts, and he has contributed to both national and international treatment recommendations. He is also Director of the Professional Section of Diabetes Québec and a member of the Canadian Academy of Health Sciences. The main objective of his team's research program is to reduce the burden of hypoglycemia for individuals with type 1 diabetes. He was one of the pioneers in the development of the artificial pancreas. He also studies the causes and consequences of diabetes in individuals living with cystic fibrosis.
Participants should be aware of the following financial/non-financial relationships:
Remi Rabasa-Lhoret MD, PhD: Abbott Canada: Advisory Board (Ongoing); Abbott Canada: Consultant (Ongoing); Abbott Canada: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Abbott Canada: Speaker/Honoraria (Ongoing); AstraZeneca: Advisory Board (Ongoing); AstraZeneca: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Terminated); Bayer Inc.: Consultant (Terminated); Boehringer-Ingelheim: Advisory Board (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Boehringer-Ingelheim: Speaker/Honoraria (Ongoing); CIHR: Grant/Research Support (Ongoing); cms Canadian&Surgical Knowledge Translation Research: Speaker/Honoraria (Terminated); Cystic fibrosis Canada: Grant/Research Support (Ongoing); Dexcom Canada: Consultant (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Diabetes Canada: Grant/Research Support (Ongoing); E Lilly: Advisory Board (Ongoing); E Lilly: Consultant (Ongoing); E Lilly: Grant/Research Support (Ongoing); E Lilly: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); E Lilly: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); E Lilly: Speaker/Honoraria (Ongoing); FFRD: Grant/Research Support (Ongoing); HLS Therapeutics: Advisory Board (Ongoing); HLS Therapeutics: Consultant (Ongoing); INESSS: Consultant (Ongoing); Insulet: Advisory Board (Ongoing); Insulet: Consultant (Ongoing); Janssen: Advisory Board (Ongoing); Janssen: Consultant (Ongoing); Janssen: Grant/Research Support (Ongoing); Janssen: Speaker/Honoraria (Ongoing); JDRF Canada: Grant/Research Support (Terminated); Medtronic: Consultant (Ongoing); Medtronic: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); Merck: Consultant (Terminated); Merck: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Terminated); Merck: Speaker/Honoraria (Terminated); NIH: Grant/Research Support (Terminated); Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Consultant (Ongoing); Novo Nordisk Canada Inc.: Grant/Research Support (Ongoing); Novo Nordisk Canada Inc.: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing); Pfizer: Consultant (Terminated); Sanofi: Advisory Board (Ongoing); Sanofi: Consultant (Ongoing); Sanofi: Grant/Research Support (Ongoing); Sanofi: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Sanofi: Speaker/Honoraria (Ongoing); SFD: Grant/Research Support (Ongoing); Tandem: Speaker/Honoraria (Ongoing); Vertex: Grant/Research Support (Terminated); Vertex: Speaker/Honoraria (Terminated)
Presenting at:
Hypoglycemia: Risk Considerations and New Strategies - 8:00 AM, Novermber 12th
Dr. Perkins is Professor, Endocrinologist, Epidemiologist and Clinician-Scientist at the University of Toronto Faculty of Medicine and IHPME. He holds the Sam and Judy Pencer Family Chair in Diabetes Clinical Research. His research platform, research leadership, clinical practice and advocacy work has focused entirely on strategies to improve the lives of those, like himself, living with type 1 diabetes. Using cohort and trial methods, his research has focused on 1.) Early biomarkers and mechanisms of diabetes complications, and 2.) complications prevention through artificial pancreas technologies and add-on-to-insulin drug therapies. Among leadership in other projects funded by CIHR, NIH and JDRF, he sits on the Executive of the historic but ongoing “DCCT/EDIC” Study, and co-leads the Innovations in Type 1 Diabetes Goal Group within Diabetes Action Canada, a national patient-oriented research strategy. He has been awarded the Canadian Diabetes Association/CIHR Young Scientist Award.
Participants should be aware of the following financial/non-financial relationships:
Bruce A. Perkins MD, MPH: Abbott: Advisory Board (Ongoing); Abbott: Speaker/Honoraria (Ongoing); Insulet: Advisory Board (Ongoing); Insulet: Speaker/Honoraria (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); novo nordisk: Advisory Board (Ongoing); novo nordisk: Grant/Research Support (Ongoing); novo nordisk: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing); Sanofi: Speaker/Honoraria (Ongoing)
Presenting at:
Continuous Glucose Monitoring — Practical Approaches - 1:30 PM, November 9th
Dr. Parisien-La Salle completed the Endocrinology and Metabolism residency program of the University of Montreal in 2020. She graduated on the Dean’s honor list. She is now pursuing a fellowship in the genetics of adrenal disease at the CRCHUM (Centre de recherche du centre hospitalier de l’Université de Montréal) under the supervision of Dr. Isabelle Bourdeau, and is completing the Clinician-Investigator program and a PhD in Biomedical Sciences. During her studies, Dr. Parisien-La Salle has won several prizes for her research (17 for a total of $50,000), including the John Dupré and Sonia Salisbury prizes at the annual conferences of the CSEM in 2019 and 2021, the Pavel Hamet Research Award from the CRCHUM in 2022, as well as the “Outstanding Abstract” award at the ENDO Society in 2020. She has also published six articles in the last three years. To finance part of her PhD, Dr. Parisien-La Salle obtained the prestigious research training salary grant “bourse de formation de recherche: phase 1 du FRQS (Fonds de recherche du Québec en santé)”. This is a salary grant of $73,000 per year (2020-2022). She ranked first in this Quebec competition. In addition, in 2021, she obtained a research grant of $10,000 from the Federation of Resident Physicians of Quebec (FMRQ) Grant Program to support part of her research projects. Following her post-doctoral studies, she will complete a fellowship at Harvard Medical School in Boston, MA, on primary aldosteronism under the supervision of Dr. Anand Vaidya. Dr. Parisien-La Salle will then return to the Montreal to work at the CHUM as a clinician investigator in adrenal disease.
Participants should be aware of the following financial/non-financial relationships:
Stefanie Parisien-La Salle MD: Nothing to Disclose
Presenting at:
Spotlight on Up and Coming Scientists - 12:15 PM, Novermber 11th
Sii.ngaay 'laa. My name is Jessie and I am from the Gak’yaals Kiigaway (clan) of K’uuna (Skedans) and a member of the Haida Nation. I am Haida on my maternal side and Heiltsuk and Kwakwaka’wakw on my paternal side. I grew up in Hlgaagilda (Skidegate, Haida Gwaii) and W̓áláqvḷa (Bella Bella, BC), and I am from two fishing families. I was fortunate to have access to many of my ancestral foods in my youth and have always loved how they bring family and community together. I completed my Dietetics degree at the University of British Columbia in 2015 and currently hold the position of Indigenous Health Dietitian with Island Health, working with Northern Vancouver Island communities towards achieving their wellness goals. This includes supporting Nations in their food sovereignty/security initiatives, as well as diabetes prevention and management. From an early age, I understood the healing power of our foods, and feel fortunate that “work” allows continual learning and guidance from community knowledge keepers.
Participants should be aware of the following financial/non-financial relationships:
Jessie Newman RD: Nothing to Disclose
Presenting at:
Journey towards Indigenous Cultural Safety and Humility for HCPs - 1:30 PM, Novermber 9th
Dr. Mancini is Professor of Medicine at the University of British Columbia; Director, Cardiovascular Imaging Research Core Laboratory (CIRCL); and Scientific Director, CardioRisk Clinic, Vancouver Hospital. His interest focuses on the integration of multi-modality cardiac imaging in multicenter clinical trials for assessment of structural and functional aspects of heart disease and for primary and secondary cardiovascular risk reduction. He has published over three hundred journal articles, abstracts, books and book chapters. He has co-chaired the CCS Guidelines for management of Stable Ischemic Heart Disease and the CCS Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.
Participants should be aware of the following financial/non-financial relationships:
G.B John Mancini FRCPC, FACC: AstraZeneca: Advisory Board (Ongoing); AstraZeneca: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Terminated); Boehringer Ingelheim: Consultant (Terminated); Boehringer Ingelheim: Grant/Research Support (Terminated); Boehringer Ingelheim: Speaker/Honoraria (Terminated); Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Consultant (Ongoing); Novo Nordisk Canada Inc.: Grant/Research Support (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing)
Presenting at:
Optimizing cardiovascular risk reduction in people living with diabetes - 1:15 PM, Novermber 10th
Lisa has recently started in a newly created position in BC as the Diabetes Clinical Nurse Specialist (CNS) for Providence Healthcare. She brings 34 years of nursing experience in a wide variety of areas, including renal transplant, critical care, cardiovascular and med-surg, to name a few. She has been a Certified Diabetes Educator since 2004 and a Diabetes Clinical Nurse Specialist for Hamilton Health Sciences in Ontario since 2011. She was the Clinical Coordinator for the McMaster Diabetes Clinic for several years, but most of her diabetes experience is with management and consultation of patients with complex diabetes needs admitted to hospital. The clinical competencies for this advanced practice nursing role include providing expert consultation to prescribers and holistic plans of care for patients, quality improvement projects, leadership, education (of staff, physicians, allied health teams and patients) and research. Recent awards include: Nursing Leadership, Hamilton Health Sciences 2020 PHC Research Challenge; 2022: Improving Access to Diabetes Care: Evaluation of a new clinic model to maximize the complexities of CDEs PHC Skunkworks; and 2022: On Demand Wound Services: Bringing wound care to underserved people. She is faculty at McMaster School of Nursing, Hamilton, ON, and Royal Roads University, Victoria, BC, and plans to apply for a faculty position with UBC School of Nursing in 2023. She recently initiated the BC Diabetes Collaborative, which brings key stakeholders together to share successes, challenges, tools and to create relationships across the province. She has also recently taken the role of Chair of the Board of Directors for the Clinical Nurse Specialist Association of BC. She is passionate about providing excellent management of diabetes in hospitals and incorporating value-based care in diabetes health-care services. She hopes to shape both in-patient and out-patient diabetes programs to ensure the services provided focus on what is of most value to the person with diabetes in order to improve health outcomes.
Participants should be aware of the following financial/non-financial relationships:
Lisa Maks RN, MN, CDE: Abbott Diabetes: Advisory Board (Ongoing); Abbott Diabetes: Speaker/Honoraria (Ongoing); BD: Advisory Board (Terminated); BD: Speaker/Honoraria (Terminated); CPD Network Association: Speaker/Honoraria (Terminated); Dexcom Canada: Speaker/Honoraria (Terminated); Eli Lilly: Advisory Board (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Terminated); Partners in Progressive Medical Education: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Terminated); Sanofi: Speaker/Honoraria (Terminated); St. Paul's Hospital Cardiac Education Committee: Speaker/Honoraria (Terminated); St. Paul's Research Foundation: Grant/Research Support (Ongoing)
Presenting at:
Straight to the Source: Early Glucose Control AND Weight Reduction with dual GIP/GLP-1 receptor agonism in people with T2D - 7:00 AM, November 11th
Presenting at:
CSEM 16th Annual Endocrine Residents’ Day Review Course - 8:00 AM, November 9th
Presenting at:
Experiences in Research as an Indigenous Elder with Diabetes - 4:15 PM, November 10th
Dr. Kuhnke is an Associate Professor in the School of Nursing at Cape Breton University. Before coming to the academy, she lived and worked as a clinical nurse and educator in rural communities in British Columbia, alongside Aboriginal members and communities. She is active in Wounds Canada as a nurse specialized in wound, ostomy and continence care, and she advocates for prevention of diabetes-related foot ulcers-amputations. Her doctoral psychology studies focused on quality of life, and spiritual and mental health well-being; Two-Eyed Seeing principles guided this work, as well as reflexivity practice. She supports Master’s Degree students in qualitative research projects.
Participants should be aware of the following financial/non-financial relationships:
Janet L. Kuhnke RN, BA, BScN, MS, NSWOC, PhD (Psychology): Nothing to Disclose
Presenting at:
Diabetic Foot Diseases: Illuminating the Path to Amputation Prevention for The Diabetes Healthcare Team Screening and beyond - 8:00 AM, November 12th
General Practitioner
University of Calgary, Dept Fam Med
Diabetes Canada - Steering Committee for CPG, Co-Chair of Primary Care Interest Group Calgary, AB
Dr Kim is a general practitioner in Calgary with special interest in chronic diseases, especially in diabetes and chronic migraine. He is a clinical assistant professor in the Department of Family Medicine at University of Calgary.
After graduating from his medical school in South Africa, he has completed post-graduate diploma in Diabetes in 2012 and works as a peer reviewer and editorial board member for numerous medical journals including Canadian Journal of Diabetes. He has given numerous presentations locally, nationally and internationally on various topics such as diabetes, chronic migraine, binge eating disorder, ADHD, and respiratory medicine. He has also been involved in numerous CME slide deck development.
Within Diabetes Canada, his role includes steering committee member for the Clinical Practice Guideline, current co-chair of Primary Care Special Interest Group, Dissemination and Implementation member and has been a scientific planning committee member for the Annual Diabetes Canada Conference.
Presenting at:
How We See It: Interdisciplinary Perspectives on GLP-1 RA Use in T2D with CV Risk - 11:45 AM, November 11th
Dr. Jung is an Associate Professor in the School of Health and Exercise Sciences at the University of British Columbia, Okanagan Campus in Kelowna, BC. Her overarching research interests lie in the area of self-regulation of health behaviours, with particular focus on dietary and exercise adherence for the prevention of type 2 diabetes. Dr. Jung’s current funded studies span health program evaluation, effectiveness of mHealth technologies, exercise counselling for individuals with prediabetes, and exercise adherence randomized controlled trials. Dr. Jung is head of the Diabetes Prevention Research Group, founder of the diabetes prevention program “Small Steps for Big Changes”, and Director of the Centre for Health Behaviour Change. Her thriving research program welcomes a growing team of trainees from across the world who study the self-regulation of diet and exercise behaviours, and program evaluation of intervention implementation and sustainability with a lens towards improving equity, diversity and inclusivity in all research endeavours. Dr. Jung’s innovative research is located in the new community-engaged research space at UBC’s Okanagan campus, as well as at multiple locations throughout communities across Canada and internationally. Working with the community in formulating what the next research endeavors are has been pivotal for Dr. Jung and the continuation of her programs, including Small Steps for Big Changes. This ensures that the research is meaningful and useful to those who will use the knowledge, whilst also strengthening her genuine commitment to partners. Dr. Jung and her team work diligently to engage community members in their research.
Participants should be aware of the following financial/non-financial relationships:
Mary Jung PhD: Centre for Collaboration, Motivation, and Innovation: Board Member (Ongoing)
Presenting at:
Putting Theory into Action: Supporting Behaviour Change in Individuals at Risk or living with Type 2 Diabetes - 4:14 PM, Novermber 10th
Dr. Jain is the first Canadian physician to be triple board-certified by the American Boards in Endocrinology, Internal Medicine and Obesity Medicine. He trained in Internal Medicine at Rochester, NY, where he became the only 4-time winner of the prestigious Rochester Academy of Medicine Awards. He completed his Fellowship in Endocrinology at Harbor UCLA/City of Hope in Los Angeles, CA. He is the only non-American physician to win the AACE Rising Star in Endocrinology Award (2022) and to feature on Medscape’s list of 25 Top Rising Stars of Medicine (2020). He is the first North American to win the prestigious Etzwiler Diabetes Scholarship at the International Diabetes Center and Mayo Clinic in MN, US. In 2017, he was awarded the Rising Star of Diabetes Award at the International Symposium on Diabetes. He is a renowned educator and has spoken at over 800 medical conferences/events across the world to date. His clinical interests include diabetes, obesity, thyroid disorders and osteoporosis. He has active YouTube/Instagram channels dedicated to patient education, with thousands of views to date. He is fluent in 6 languages, including English, Hindi, Gujarati, Marathi, Marwari and Urdu. In 2022, he won the Top 25 Canadian Immigrant Award and also received the 2022 Healthcare Achievement Award by Drishti Magazine.
Participants should be aware of the following financial/non-financial relationships:Presenting at:
The Hidden Risk Marker in Diabetes: Triglycerides and Cardiovascular Risk - 6:45 PM, November 11th
Presenting at:
Inclusion, Diversity, Equity, Accessibility (IDEA) - Diabetes management in Immigrants to Canada - 4:15 PM, November 11th
Presenting at:
The Hidden Risk Marker in Diabetes: Triglycerides and Cardiovascular Risk - 6:45 PM, November 11th
Dana (she/her) was diagnosed with type 1 diabetes (T1D) in 1972, at the age of 7. She was a professional fundraiser for over 20 years and is the proud mom of 3 kids, aged 30, 28 and 22. Fourteen years ago, her youngest daughter Marley was also diagnosed with T1D at the age of 8. After Marley's diagnosis, Dana quickly came to realize that she was in a unique position to help others because she understood both what it means to be a person living with T1D and what it means to be a parent of a child with T1D. Dana is an active volunteer with many diabetes organizations in Toronto, Ontario, where she chairs various committees and does speaking engagements. Her passion is educating others on what it means to live with what is often an invisible disease, and she has mentored dozens of families living with T1D. After years of facing stigma and barriers because of her health condition, Dana is driven to advocate for others in the community so that they are not faced with the same lack of understanding and discrimination she faced growing up with T1D. Dana has been involved with Diabetes Action Canada (DAC) as a patient partner since 2017. Dana is co-chair of DAC’s Patient Engagement Committee, is a member of DAC's Steering Committee and Collective Patient Circle, and is a patient partner on many research projects.
Participants should be aware of the following financial/non-financial relationships:
Dana Greenberg: Diabetes Action Canada: Committee/Planning Member (Ongoing); Diabetes Action Canada: Independent Contractor (Ongoing); Diabetes Action Canada: Speaker/Honoraria (Ongoing)
Presenting at:
Role of Patient-Oriented Research in Developing New Models of Care - 10:15 AM, November 10th
Joanne graduated with a Bachelor of Science in Foods and Nutrition from Brescia College at Western University in London, Ontario. She completed a Dietetics Internship at Sunnybrook Hospital in 1999. She has worked as a Registered Dietitian for 23 years and has been a Certified Diabetes Educator since 2002. She has worked as a dietitian in home care, adult hemodialysis and both pediatric and adult diabetes throughout her career. She began working at McMaster Children's Hospital exclusively in pediatric diabetes in 2017. She is a certified product trainer for all of the available insulin pumps, and she has a passion for supporting families in using technology to support their diabetes management.
Participants should be aware of the following financial/non-financial relationships:
Jeannette M. Goguen MD, MEd, FRCPS: Nothing to Disclose
Presenting at:
Diabetes in the Child/Adolescent - 8:00 AM, November 12th
Joanne graduated with a Bachelor of Science in Foods and Nutrition from Brescia College at Western University in London, Ontario. She completed a Dietetics Internship at Sunnybrook Hospital in 1999. She has worked as a Registered Dietitian for 23 years and has been a Certified Diabetes Educator since 2002. She has worked as a dietitian in home care, adult hemodialysis and both pediatric and adult diabetes throughout her career. She began working at McMaster Children's Hospital exclusively in pediatric diabetes in 2017. She is a certified product trainer for all of the available insulin pumps, and she has a passion for supporting families in using technology to support their diabetes management.
Participants should be aware of the following financial/non-financial relationships:
Joanne Gibson BSc, RD, CDE: Nothing to Disclose
Presenting at:
Diabetes in the Child/Adolescent - 8:00 AM, November 12th
Dr. Gilbert completed his Medical Degree, Internal Medicine training and Endocrinology residency at the University of Toronto. He is an associate professor at the University of Toronto, and the former Program Director for adult endocrinology and metabolism at the University of Toronto. He has authored chapters in the 2013 and 2018 Diabetes Canada Clinical Practice Guidelines (CPG). He was a member of the 2018 CPG Steering Committee and is also a current member of the CPG Steering Committee. He is the national lead for dissemination and implementation for the Diabetes Canada CPG. Dr. Gilbert is on the Executive and is a National Editor for the Canadian Journal of Diabetes. He is the Endocrinology Section Chair at the Royal College and Surgeons of Canada. He is a passionate teacher and his academic interests lie in undergraduate, postgraduate and continuing medical education in diabetes and endocrinology. He has received numerous awards for outstanding teaching, including the 2021 Canadian Society of Endocrinology and Metabolism's Harvey Guyda Educator of the Year Award.
Participants should be aware of the following financial/non-financial relationships:
Jeremy Gilbert MD, FRCPC: Abbott Canada: Advisory Board (Ongoing); Abbott Canada: Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); AstraZeneca: Advisory Board (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Ongoing); Bayer Inc.: Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Eli Lilly: Advisory Board (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Janssen: Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing); Sanofi: Speaker/Honoraria (Ongoing)
Presenting at:
Eureka Moments: How rtCGM has Changed our Practice - 6:00 PM, November 9th
Presenting at:
Straight to the Source: Early Glucose Control AND Weight Reduction with dual GIP/GLP-1 receptor agonism in people with T2D - 7:00 AM, November 11th
I am Fiona, White Settler of Irish ancestry. I am a daughter, sister, auntie, friend and lifelong learner. My family immigrated to the Treaty 6 Territory and the homeland of the Métis colonially known as Saskatoon. I occupy and benefit off unceded Coast Salish homelands of the Ləkʷəŋən Speaking Peoples of Songhees (Ləkʷəŋən) and Esquimalt (Xwepsum) Nations. I occupy and benefit from unceded, ancestral, and stolen homelands of Ləkʷəŋən Speaking Peoples of Songhees (Ləkʷəŋən) and Esquimalt (Xwepsum) Nations. Before Canada, British Columbia and Victoria were formed, this place was known as Metulia (Ləkʷəŋən). Ləkʷəŋən means ‘a place to smoke herring.’ I picture the vast amounts of herring being smoked and preserved. These lands and the environment are foundational to wellbeing. Healthy lands, healthy peoples. Each day, I acknowledge this deep connection and advocacy for the lands, waters and forests. In this, I must bring forward the vast colonial policies that impact and shape the lives of all Indigenous families here on the island. I commit to learning more, listening deeply, reflecting on my power and privilege. I will continue to take steps to dismantle and disrupt racism within the society. I hope to build relationships with others who want to reflect on our collective responsibility to address these inequities and work towards social justice. I have been honoured to have a long career working as a dietitian alongside Coast Salish, Kwakwaka'wakw and Nuu-chah-nulth communities. I have completed two apprenticeships in Herbal Medicines and I am currently completing an MSc Social Dimensions of Health on Indigenous-Specific Racism. I spend my time with family, friends, hiking, camping, gardening and learning about the plants.
Participants should be aware of the following financial/non-financial relationships:
Fiona M. Devereaux MSc SDH Candidate: Nothing to Disclose
Presenting at:
Journey towards Indigenous Cultural Safety and Humility for HCPs - 1:30 PM, Novermber 9th
Presenting at:
CSEM 16th Annual Endocrine Residents’ Day Review Course - 8:00 AM, November 9th
Presenting at:
NIDA and his journey with Diabetes - 10:15 AM, November 11th
Presenting at:
The Hidden Risk Marker in Diabetes: Triglycerides and Cardiovascular Risk - 6:45 PM, November 11th
Kari is a patient in the Red Deer Bariatric Program. She had gastric band (LAP-Band) surgery in 2009 and revision to gastric bypass on May 30 2021. She is sharing her personal story about the struggles and successes she experienced as a person who has undergone bariatric surgery.
Participants should be aware of the following financial/non-financial relationships:
Kari C. Duarte: Nothing to Disclose
Presenting at:
Diabetes and Bariatric Surgery - 4:15 PM, November 11th
Dr. Connelly is a Cardiologist and Scientist who is nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation with a focus upon translating discoveries into therapies in humans. He has an H-index of 48 and i10-index of 158 (Google scholar), and his work has been cited >8,100 times, with publications in journals, including the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes. His work is diverse, covering clinical guidelines statements, clinical trials, and preclinical studies along the themes of ventricular remodeling, diabetes, magnetic resonance imaging and echocardiography. He is a member of the Editorial Board of various journals, including The Canadian Journal of Cardiology and Cardiovascular Diabetology. He has received funding from the Heart and Stroke Foundation Canada, CIHR, Canadian Foundation of Innovation, Ministry of Ontario and industry sources, totally >$5 million as principal investigator. As a co-investigator, he has been part of >$20 million in funding, from the Ministry of Ontario, HSF, CIHR, CFI and industry sources. Dr. Connelly has been recognised for his contributions to science by being awarded a HSF clinician scientist award, a CIHR New Investigator Award, an Early Researcher Award from the Ministry of Ontario, the SC Verma award and the Insulin 100 emerging leader award to celebrate 100 years since the discovery of insulin at University of Toronto, as well as Canadian Cardiovascular Congress YIA 2012. He is current Chair of the Canadian Cardiovascular guideline and was Chair of the macrovascular complications section for the Diabetes Canada 2018 Clinical Practice Guidelines. Dr. Connelly is the director of the Keenan Research Centre for Biomedical Science and holds the Keenan Chair in Research Leadership.
Presenting at:
Heart Failure with preserved Ejection Fraction in Diabetes: Novel Mechanisms and treatments - 10:15 AM, November 10th
Barbara has worked at the Leadership Sinai Centre for Diabetes for over 30 years and is cross appointed to the University of Toronto Nursing faculty. Her primary clinical focus is diabetes in pregnancy, technology, and inpatient consultation. However, she works together with all patients with diabetes. She has published research on self-management education and diabetes in pregnancy. She co-authored two Diabetes Canada publications for diabetes educators (The Essentials and Advancing Practice) and she has presented numerous workshops for diabetes educators. As part of the team, she provides education programs for CDECB exam preparation. She volunteers through various diabetes organizations, including Diabetes Canada and Type 1 Think Tank. She received the 2011 Banting and Best Diabetes Educator of the Year Award and Diabetes in Pregnancy Special Interest Group Award from Diabetes Canada in 2016. Also, the Leadership Sinai Centre for Diabetes team received the 2022 Diabetes Team of the Year Award from the Banting and Best Diabetes Centre.
Participants should be aware of the following financial/non-financial relationships:
Barbara Cleave RN, MN, CDE: Dexcom Canada: Speaker/Honoraria (Terminated); Diabetes Care community: Consultant (Terminated); Medtronic: Independent Contractor (Ongoing); novo nordisk: Advisory Board (Terminated); Sanofi: Advisory Board (Ongoing); Sanofi: Speaker/Honoraria (Ongoing)
Presenting at:
Beyond A1C: The Emerging Role of Time in Range - 6:45 PM, November 10th
Presenting at:
Eureka Moments: How rtCGM has Changed our Practice - 6:00 PM, November 9th
Presenting at:
CSEM 16th Annual Endocrine Residents’ Day Review Course - 8:00 AM, November 9th
Presenting at:
The Hidden Risk Marker in Diabetes: Triglycerides and Cardiovascular Risk - 6:45 PM, November 11th
Dr. Blanchette is the first podiatrist PhD in Québec and has been an associate professor in the Podiatric Medicine program at Université du Québec at Trois-Rivières since 2014. Her research specialty is prevention and management of diabetic foot ulcers and their complications, with a team approach within patient-oriented research (POR). Her research program focuses on knowledge translation for limb preservation. She is a Diabetes Action Canada trainee and has conducted one postdoctoral fellowship in shared decision-making, knowledge translation and implementation science, with Dr. France Légaré at Université Laval, as well as one in limb preservation at the University of Southern California on David G. Armstrong's team. Dr. Blanchette holds a PhD in Biomedical Sciences from Université de Montréal, a Doctorate in Podiatric Medicine (DPM), and a Master’s Degree and Bachelor’s Degree in Medical Biology from Université du Québec à Trois-Rivières (UQTR). She joined the Canadian Diabetic Foot Task Force in 2019 to help prevent, manage and address the deficit in awareness, knowledge, and funding of diabetes-related foot complications, preventable amputations and loss of life of people living with diabetes in Canada. She is a member of many research networks and works in collaboration with many associations, including Wounds Canada, Société de santé vasculaire du Québec and many others. She is a passionate agent of change in her field and wants to make a difference for Canadians living with diabetes and its complications, but also for others by building capacity, collaboration, leadership and research.
Virginie Blanchette BSc, MSc, DPM, PhD: American LImb Preservation Society: Committee/Planning Member (Ongoing); American LImb Preservation Society: Grant/Research Support (Ongoing); Diabète Québec: Grant/Research Support (Ongoing); Diabetes Action Canada: Grant/Research Support (Ongoing); Ordre des podiatres du Québec: Committee/Planning Member (Ongoing); Ordre des podiatres du Québec: Consultant (Ongoing); Ordre des podiatres du Québec: Grant/Research Support (Ongoing); Ordre des podiatres du Québec: Speaker/Honoraria (Ongoing); Regroupement Québécois en Soins des Plaies: Board Member (Ongoing); Regroupement Québécois en Soins des Plaies: Speaker/Honoraria (Ongoing); Wounds Canada: Board Member (Ongoing); Wounds Canada: Committee/Planning Member (Ongoing); Wounds Canada: Consultant (Ongoing); Wounds Canada: Grant/Research Support (Ongoing); Wounds Canada: Speaker/Honoraria (Ongoing)
Presenting at:
Diabetic Foot Diseases: Illuminating the Path to Amputation Prevention for The Diabetes Healthcare Team Screening and beyond - 8:00 AM, November 12th
Presenting at:
CSEM 16th Annual Endocrine Residents’ Day Review Course - 8:00 AM, Novm,ber 9th
Lori has 35 years of experience in diabetes education, management and clinical research working as the Nurse Manager for the Health Sciences Centre Diabetes Research Program. She was also a Faculty Member at the University of Manitoba, Department of Medicine, Section of Endocrinology. Currently, she is working as a consultant in diabetes management and clinical research operations. Lori has dedicated many years volunteering with Diabetes Canada and has extensive experience with the Clinical Practice Guidelines. She has been part of over 100 peer-reviewed publications and has received many honors and awards related to her work in diabetes.
Participants should be aware of the following financial/non-financial relationships:
Lori Berard, RN, CDE: Abbott Diabetes: Advisory Board (Ongoing); Abbott Diabetes: Committee/Planning Member (Ongoing); Abbott Diabetes: Speaker/Honoraria (Ongoing); AstraZeneca: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Consultant (Ongoing); Bayer Inc.: Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Speaker/Honoraria (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing); EMBECTA: Consultant (Ongoing); EMBECTA: Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); MontMed: Advisory Board (Ongoing); MontMed: Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Consultant (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing); Roche: Consultant (Ongoing); Roche: Speaker/Honoraria (Ongoing); Sanofi: Consultant (Ongoing); Sanofi: Speaker/Honoraria (Ongoing); Viatriis: Advisory Board (Ongoing)
Presenting at:
Straight to the Source: Early Glucose Control AND Weight Reduction with dual GIP/GLP-1 receptor agonism in people with T2D - 7:00 AM, November 11th
How We See It: Interdisciplinary Perspectives on GLP-1 RA Use in T2D with CV Risk - 11:45 AM, November 11th
Dr. Benham is an Assistant Professor in the Departments of Medicine and Community Health Sciences at the Cumming School of Medicine, University of Calgary and an Endocrinologist at Alberta Health Services - Calgary Zone. She completed a Bachelor of Human Kinetics in Exercise Science and Doctor of Medicine at the University of British Columbia followed by clinical training at the University of Calgary in Internal Medicine and Endocrinology and Metabolism. In addition, she completed a Doctor of Philosophy in Epidemiology from the University of Calgary, and a Royal College accredited Clinician Investigator Program research fellowship. Her research training was supported by a Dr. Fernand Labrie Fellowship Research Grant from the Canadian Society of Endocrinology and Metabolism. Her clinical focus is in reproductive endocrinology, including polycystic ovary syndrome and diabetes in pregnancy. Her research program focuses on reproductive and cardiometabolic health across the lifespan in individuals with reproductive endocrine disease.
Presenting at:
CSEM 16th Annual Endocrine Residents’ Day Review Course - 8:00 AM, November 9th
Presenting at:
Endocrinologists Diabetes Quiz Show (the rules are very similar to Jeopardy), hosted by Dr. Bruce Perkins - 11:45 AM, November 10th
Dr. Kibbey graduated from Trinity University in San Antonio with a BA in Music and a BS in Biochemistry, and he earned his MD and PhD in Molecular Biophysics from the University of Texas Southwestern Medical School in Dallas. He came to Yale University in 2000 on the ABIM short track and for his Internal Medicine internship and residency, as well as an Endocrinology fellowship. He remained at Yale to start his lab and he has a secondary appointment in Cellular & Molecular Physiology. He is also a member of the Yale Center for Molecular and Systems Metabolism. He is an Associate Professor with tenure, Associate Director of the Program in Translational Biomedicine, and Director of the IOMIC facility for metabolism. His lab focus is on mitochondrial metabolism, in particular, as it pertains to glucose sensing in the pancreatic beta cell.
Participants should be aware of the following financial/non-financial relationships:
Richard Kibbey MD PhD: Boehringer Ingelheim: Advisory Board (Ongoing); Eli Lilly: Advisory Board (Ongoing); Eli Lilly: Consultant (Ongoing); Eli Lilly: Speaker/Honoraria (Terminated); Eli Lilly: Speaker/Honoraria (Ongoing); Elucidata: Advisory Board (Ongoing); Elucidata: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); intellihealth: Advisory Board (Ongoing); novo nordisk: Advisory Board (Ongoing); pangolin: Advisory Board (Ongoing); Pfizer: Advisory Board (Ongoing); rhythm pharmaceuticals: Advisory Board (Ongoing); Scholar Rock: Consultant (Ongoing); weight watchers: Advisory Board (Ongoing)
Presenting at:
Novel mechanisms of insulin secretion - 10:15 AM, Novermber 10th
Dr. Laidley completed his medical school training at Memorial University of Newfoundland and Labrador and subsequently completed his Nuclear Medicine residency training at Western. He later completed a PET-CT fellowship in Oncology at McGill University and further theranostic fellowship training at Western. Currently, Dr. Laidley is an Associate Professor of Nuclear Medicine and Program Director of the Nuclear Medicine residency program. His practice is primarily focused on theranostics, and he is the current lead for Western’s PRRT program and co-chair of London’s neuroendocrine multidisciplinary program. Dr. Laidley is currently involved in a number of national and international therapy trials, including the NETTER-2 PRRT trial and various PMSA-based trials, including VISION, AAROW and PLUDO.
Participants should be aware of the following financial/non-financial relationships:
David T. Laidley MSc, MD: AAA/Novartis: Advisory Board (Ongoing); AAA/Novartis: Consultant (Ongoing); Bayer: Advisory Board (Terminated); Ipsen: Advisory Board (Ongoing)
Presenting at:
Nuclear medicine: Lessons to learn for the endocrinologist - 10:15 AM, November 10th
Presenting at:
Future of Obesity Medications - 8:30 AM, November 11th
Seeta is currently the longest standing member of the Montreal Children’s Hospital Family Advisory Forum. She represents the MUHC Patients’ Committee on the Board of Directors of the McGill University Health Centre (MUHC) and she is known for her dedication to the advancement of equitable health care for patients and families, in particular, for encouraging cultural sensitivity with respect to ethnicity, race, religion, language, disability, gender, sexual orientation and socioeconomic factors. A member of the Conseil de la protection des malades, she also serves as the co-chair for the Committee for Action on Inclusion, Diversity and Equity (C-AIDE) on behalf of the MUHC Board, as a key member involved in the consultation process with the Québec government’s Groupe d’action contre le racism, and as a member of the SCSA of the Association of Faculties of Medicine of Canada. She has also served on task forces for the McGill University Faculty of Medicine and Health Sciences, as well as for other local and international hospitals and university networks. Due to a career spanning over 25 years in the health care public relations and communications field, including as Director of Public Relations and Communications for St. Mary’s Hospital Center, and in her patient advocacy roles, she has promoted the clinical, teaching and research successes of the hospitals, universities and foundations with which she has worked. She has also been instrumental in producing medical reports, news stories and documentaries, including over 100 broadcasts on a variety of health topics, medical features with Australian Broadcasting Corporation and the Doctor*ology medical series starring Leslie Nielsen for the Discovery and Learning channels. An alumna of McGill University, Seeta has also completed training programs in patient safety. She has been honoured for her work in the community with an Award of Recognition from the city of Montreal and as Spokesperson of the Year by the Indo-Canadian Cultural Association, amongst other awards. Seeta is fluent in English and French, and speaks several other languages.
Participants should be aware of the following financial/non-financial relationships:
Seeta Ramdass: Nothing to Disclose
Presenting at:
Role of Patient-Oriented Research in Developing New Models of Care - 10:15 AM, November 10th
Presenting at:
Kidney disease and advocacy for Indigenous patients - 8:00 AM, November 12th
TBA
Presenting at:
Endocrinologists Diabetes Quiz Show (the rules are very similar to Jeopardy), hosted by Dr. Bruce Perkins - 11:45 AM, November 10th
Ryan is the Program Lead Advocacy and Come To Work with the CNIB Foundation. Ryan was diagnosed with type 1 diabetes at the age of 7 and woke up one morning in 2011 with detached retinas. He has not let this slow him down. He is the father to a 3-year-old daughter, Abigail, and handler to a CNIB-certified guide dog, a yellow lab named Joe. Ryan is an avid volunteer with Diabetes Canada, working on several different projects, including the fight for an accessible insulin pump. In conjunction with the CNIB, Diabetes Canada has been able to make strides toward making this a reality. Ryan attended Spring Arbor University in Michigan where he was a scholarship athlete, playing varsity baseball while obtaining his BA in Marketing and Public Relations. He then continued his education at the University of Windsor with a BA in Sociology and a diploma from Mohawk College in Volunteer Management and Coordination.
Participants should be aware of the following financial/non-financial relationships:
Ryan Hooey: Nothing to Disclose
Presenting at:
Role of Patient-Oriented Research in Developing New Models of Care - 10:15 AM, November 10th
Presenting at:
Endocrinologists Diabetes Jeopardy with your Jeopardy host Dr. Bruce Perkins - 11:45 AM, November 10th
Presenting at:
Endocrinologists Diabetes Jeopardy with your Jeopardy host Dr. Bruce Perkins - 11:45 AM, November 10th
Dr. Cardinal is a First Nation Physician from the Saddle Lake First Nation. In addition to practising in her home community of Saddle Lake as a family physician, she also works in St. Paul, Alberta as a rural family physician. Her work includes: clinic, emergency room, long-term care, Site Director for third-year medical students during their rural rotation, and Clinical Lead in Post Graduate Education at the Faculty of Medicine at the University of Alberta. She volunteers on the following boards: management committee member of the Indigenous Wellness Program Alternative Relationship plan, physician council member in the College of Physicians and Surgeons, and board member for the Lakeland PCN.
Participants should be aware of the following financial/non-financial relationships:
Nicole Cardinal MD: Nothing to Disclose
Presenting at:
Barriers to Care for Indigenous Communities - 8:30 AM, November 10th
After completing a Bachelor of Science in physiotherapy, Dr. Bassilious completed her Medical Doctor degree at McMaster University followed by a pediatric residency and pediatric endocrinology fellowship at the Hospital for Sick Children, Toronto. Driven by a passion for medical education, she completed a Masters of Health Professions Education at the University of Illinois Chicago, with a thesis focused on patient education and the effects of a novel video game on diabetes management in adolescents with type 1 diabetes. After joining the Department of Pediatrics at McMaster, she took on the role of Program Director of the Pediatric Endocrinology residency program which gained Royal College accreditation in 2015. She has a particular interest in curriculum design and innovations in the delivery of medical education to the spectrum of learners, including patients and families. She is an investigator with Diabetes Action Canada, with a focus on innovations in type 1 diabetes. She is currently the Associate Chair Education for the Department of Pediatrics at McMaster, where she has the privilege of working with colleagues, learners and patient partners in innovating and continuously improving the educational offerings of the department.
Participants should be aware of the following financial/non-financial relationships:
Ereny Bassilious FRCPC, MHPE: Nothing to disclose
Presenting at:
Diabetes in the Child/Adolescent - 8:00 AM, November 12th
Dr. Carreau is an Endocrinologist, Clinician-Scientist and Assistant Professor at Centre de Recherche CHU de Québec-Université Laval. She was trained in endocrinology at Université de Sherbrooke and completed a research fellowship studying the metabolic impact of bariatric surgery on type 2 diabetes improvement and dietary fatty acid metabolism. She completed a second research fellowship at University of Colorado/Children's Hospital Colorado studying metabolism in non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome in adolescents, funded by a postdoctoral fellowship award from Diabetes Canada. Her research focus is understanding the metabolic links between NAFLD and type 2 diabetes and polycystic ovarian syndrome. She developed a multidisciplinary specialized clinic for the assessment and treatment of NAFLD at CHU de Québec-Université Laval, arrimed with a prospective research program, studying insulin resistance and liver metabolism in NAFLD.
Participants should be aware of the following financial/non-financial relationships:
Anne-Marie Carreau MD, MSc: Nothing to disclose
Presenting at:
Beyond A1C: The Emerging Role of Time in Range - 6:45 PM, November 10th
Annabell has been a practicing Registered Nurse for 25 years, during which time she acquired her Master’s in Nursing. She has been working as a Certified Diabetes Educator and a Certified Pump Trainer for the last 16 years, and she practices in downtown Toronto at St. Michael's Hospital. She and her colleagues (educators and endocrinologists) use a team approach to manage the diverse population there. Their centre provides services to individuals 18 years and older with type 1 and type 2 diabetes. They also have a specialized clinic for young adults aged 18-24 years, and also one for gestational diabetes. Their aim is to empower individuals to be stewards of their own health to achieve the best possible outcomes.
Participants should be aware of the following financial/non-financial relationships:
Annabell Hall RN MN CDE: Nothing to disclose
Dr. Yu is a Staff Endocrinologist at St. Michael’s Hospital, an Associate Professor in the Faculty of Medicine and Dalla Lhana School of Public Health, and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is the past Co-Chair of the Clinical Practice Guidelines Dissemination and Implementation Committee of Diabetes Canada, where-in she developed evidence-based and innovative strategies to put guidelines into practice and improve the quality of diabetes care across Canada. Other research interests include shared decision-making, e-health technologies, patient and clinician experiences in health care, mentorship in academic medicine, and continuing professional development. She is passionate about teaching and engaging learners using evidence-based techniques, and is proud to work closely (and co-present!) with her amazing diabetes education team to provide the best care for their patients.
Participants should be aware of the following financial/non-financial relationships:
Catherine Yu MD, FRCPC, MHSc: Nothing to disclose
Presenting at:
Continuous Glucose Monitoring — Practical Approaches - 1:30 PM, November 9th
Dr. Halperin is an adult endocrinologist at Sunnybrook Health Sciences in Toronto and an Assistant Professor at the University of Toronto. She has a large practice of type 1 diabetes (T1D), with a special focus on young adults and pregnant women. Ilana is a strong believer that the person living with T1D is the expert on their own condition and that her job is to support them with tips and tricks to live a long, healthy life. She is a strong advocate for the use of advanced technologies and has been invited to speak nationally and internationally on the application of advanced technologies and new glycemic metrics in clinical practice.
Participants should be aware of the following financial/non-financial relationships:
Ilana J. Halperin MD, MSc, FRCPC: Abbott Diabetes: Advisory Board (Ongoing); Abbott Diabetes: Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing); Sanofi: Speaker/Honoraria (Ongoing)
Presenting at:
Eureka Moments: How rtCGM has Changed our Practice - 6:00 PM, November 9th
Beyond A1C: The Emerging Role of Time in Range - 6:45 PM, November 10th
CPG Update: New Remission - 1:15 PM, November 11th
Dr. Yu is a Staff Endocrinologist at St. Michael’s Hospital, an Associate Professor in the Faculty of Medicine and Dalla Lhana School of Public Health, and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is the past Co-Chair of the Clinical Practice Guidelines Dissemination and Implementation Committee of Diabetes Canada, where-in she developed evidence-based and innovative strategies to put guidelines into practice and improve the quality of diabetes care across Canada. Other research interests include shared decision-making, e-health technologies, patient and clinician experiences in health care, mentorship in academic medicine, and continuing professional development. She is passionate about teaching and engaging learners using evidence-based techniques, and is proud to work closely (and co-present!) with her amazing diabetes education team to provide the best care for their patients.
Participants should be aware of the following financial/non-financial relationships:
Catherine Yu MD, FRCPC, MHSc: Nothing to disclose
Presenting at:
Continuous Glucose Monitoring — Practical Approaches - 1:30 PM, November 9th
Dr. Lemieux is an Endocrinologist at CHU de Québec, Quebec City Clinical and reseach fellowship in Endocrine disorders in pregnancy in Calgary with national leading experts in the field, special interest in technologies and type 1 diabetes in pregnancy Sub-site PI of Canadian multicentric clinical trials with use of technologies in pregnant women with type 1 diabetes Head of the diabetes in Pregnancy Clinic at CHU de Québec
Participants should be aware of the following financial/non-financial relationships:
Patricia Lemieux MD: Nothing to disclose
Presenting at:
Continuous Glucose Monitoring — Practical Approaches - 1:30 PM, November 9th
Dr. Sawka is a Clinician Scientist at University Health Network and Professor in the Division of Endocrinology, Department of Medicine, at the University of Toronto. She holds a PhD in Health Research Methodology/Biostatistics and Epidemiology from McMaster University. Her research focus is primarily in thyroid cancer. Dr. Sawka’s research is funded by the Canadian Institutes of Health Research, the Canadian Cancer Society, and the University Health Network. She has been active in clinical practice guideline development and clinical practice guideline methodology at the American Thyroid Association. She is currently the Editor-in-Chief of the journal Thyroid. She was recently awarded a Scientific Merit Award and the Paul Walfish Award for Continuing Professional Development Education, from the University of Toronto.
Participants should be aware of the following financial/non-financial relationships:
Anna M. Sawka MD, PhD: Thyroid, ATA: Independent Contractor (Ongoing)
Presenting at:
Thyroid Cancer: Controversies in RAI Dosing and Primary Surveillance - 4:15 PM, November 10th
Jenna completed her undergraduate degree in Human Nutrition at the University of Guelph in 2008 and her dietetic internship through the Ottawa Hospital in 2009. She has been working as a clinical RD for over 12 years in rural Ontario, between long-term care, primary care and private practice. Her work history also includes teaching nutrition courses for the Algonquin College Food Service Worker program, as well as Nutrition Manager in the Dietary Department at the Deep River Hospital. Her favourite accomplishments include development of “Kids in the Kitchen”, a six-week, school-based cooking and nutrition program and, more recently, co-development of a six-week multidisciplinary virtual Eating Disorder Support Program. She has been sharing her nutrition knowledge via her online blog and via the North Renfrew Times newspaper and was recently awarded the 2021 Best Freelance Column from the Ontario Community Newspapers Association. She recently presented at Diabetes Canada's Diabetes Frontline Forum, and was a presenter and member of the Program Scientific Committee for the Diabetes Simplified accredited program. Outside of her private practice, she works part time between three family health teams and long-term care, working to normalize food for all patients and clients. As a wife and mom of three daughters, Jenna firmly believes that children belong in the garden and the kitchen. She added CDE to her resume in 2017, and continues to enjoy simplifying diabetes management for patients of all ages.
Participants should be aware of the following financial/non-financial relationships:
Jenna Walsh RD, CDE: Phoenix Centre for Children and Families: Speaker/Honoraria (Terminated)
Presenting at:
Diabetes and Nutrition - 4:15 PM, Novermber 10th
Dr. Kichler is an Associate Professor and a Clinical and Health Psychologist in the Department of Psychology at the University of Windsor. She specializes in clinical intervention research focusing on psychosocial adjustment and coping with type 1 diabetes in youth and families. She previously worked as a diabetes psychologist and a Certified Diabetes Care and Education Specialist (CDCES) at two academic medical centers in the US (The Children's Hospital of Wisconsin and Cincinnati Children's Hospital Medical Center) for almost 15 years before starting at the University of Windsor in the summer of 2020. In addition, she is interested in how to most effectively support college and university-aged students with type 1 diabetes transition into young adulthood.
Participants should be aware of the following financial/non-financial relationships:
Jessica C. Kichler CDCES, PhD, CPsych: American Diabetes Association: Committee/Planning Member (Terminated); American Diabetes Association: Speaker/Honoraria (Terminated); Children with Diabetes: Speaker/Honoraria (Ongoing); CIHR: Grant/Research Support (Ongoing); College Diabetes Network: Advisory Board (Ongoing); Connected in Motion: Speaker/Honoraria (Ongoing); Diabetes Action Canada: Speaker/Honoraria (Ongoing); Diabetes Canada: Committee/Planning Member (Ongoing); Diabetes Canada: Grant/Research Support (Ongoing); JDRF Canada: Committee/Planning Member (Ongoing); JDRF Canada: Grant/Research Support (Ongoing); National Institutes of Health/NIDDK: Grant/Research Support (Ongoing); Provincial Council for Maternal and Child Health: Paediatric Diabetes Network (PDN): Committee/Planning Member (Ongoing); SSHRC: Grant/Research Support (Ongoing); University of Windsor: Grant/Research Support (Ongoing); WE-SPARK Health Institute: Grant/Research Support (Ongoing)
Presenting at:
Diabetes and Mental Health - 10:15 AM, November 10th
Dr. Telfer has been a Registered Psychologist in Calgary for over 33 years. Her practice focus has been helping people with eating disorders, disordered eating, depression and anxiety disorders. Dr. Telfer presently works at the Calgary Adult Bariatric Surgery Clinic, where she helps people with obesity prepare for successful bariatric surgery.
Participants should be aware of the following financial/non-financial relationships:
Jo Ann Telfer PhD: Nothing to Disclose
Presenting at:
Diabetes and Bariatric Surgery - 4:15 PM, November 11th
Dr. Ussher carried out his PhD training with Dr. Gary Lopaschuk at the University of Alberta (Sept 2004 – Jan 2010), where he acquired expertise in the molecular regulation of cardiac energy metabolism, with a specific focus on pharmacologically increasing cardiac malonyl CoA content to treat ischemic heart disease. Following his PhD training, Dr. Ussher trained with Dr. Daniel Drucker at the Lunenfeld-Tanenbaum Research Institute at the University of Toronto (Mar 2010 – Oct 2014) to acquire extensive expertise in incretin hormone (e.g. glucagon-like peptide-1) biology and how incretin hormones influence the cardiovascular system. In November 2014, he returned to the University of Alberta with the Faculty of Pharmacy and Pharmaceutical Sciences, where his lab investigates the mechanisms by which obesity perturbs energy metabolism and contributes to the pathophysiology of insulin resistance, nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease (e.g. heart failure). He is currently a Tier 2 Canada Research Chair in the Pharmacotherapy of Energy Metabolism in Obesity.
Participants should be aware of the following financial/non-financial relationships:
John Ussher PhD: Nothing to disclose
Presenting at:
Future of Obesity Medications - 8:30 AM, November 11th
Dr. Wasserman is a Staff Endocrinologist at The Hospital for Sick Children, where he maintains a clinical focus on treatment of pediatric endocrine neoplasms and endocrine sequelae of childhood cancer therapy. His primary research focus is on genomics of childhood endocrine tumours, as well as health-care utilization among children treated for endocrine malignancies. He is a Co-Chair of the American Thyroid Association Pediatric Thyroid Cancer Guidelines and is a member of the Children's Oncology Group Endocrine Long-Term Follow-Up Task Force for Childhood Cancer Survivors and the IGHG Task Force on Growth Hormone Use in the context of childhood malignancy. He pursued undergraduate studies at McGill University in Montreal, followed by a PhD in Developmental Genetics at the University of Cambridge, medical training at Harvard Medical School, residency at Boston Children’s Hospital and a fellowship in Endocrinology at SickKids Hospital in Toronto.
Participants should be aware of the following financial/non-financial relationships:
Jonathan Wasserman MD, PHD: Nothing to disclose
Presenting at:
Thyroid Cancer: Controversies in RAI Dosing and Primary Surveillance - 4:15 PM, November 10th
Dr. Mindrum practices general internal medicine in Kentville, Nova Scotia. His clinical interests are in metabolism, diabetes, obesity, cardiometabolic health and behavioural change. He graduated from the University of Louisville School of Medicine and completed his residency training at the University of Hawaii, the University of Vermont, and Dalhousie University. He is a diplomate of the American Board of Obesity Medicine. Dr. Mindrum is the Medical Director of the Valley Regional Hospital diabetes centre. He previously served as head of the Department of Critical Care. He started Valley Metabolic Health to focus on improving awareness, knowledge and care of those living with obesity. He recently published a paper in the Canadian Journal of Diabetes describing changes in cardiometabolic markers in a cohort of patients living with type 2 diabetes who engaged in a very low carbohydrate ketogenic diet. He married Dr. Christa Mindrum, a family physician and Newfoundlander, which led to his migration north to Nova Scotia. He is a proud father of three beautiful children.
Participants should be aware of the following financial/non-financial relationships:
Michael Mindrum MD FRCPC: Bausch Health: Speaker/Honoraria (Ongoing); Centricity: Independent Contractor (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Diet Doctor: Consultant (Ongoing)|Novo Nordisk Canada Inc.: Advisory Board (Ongoing); Novo Nordisk Canada Inc.: Consultant (Ongoing); Novo Nordisk Canada Inc.: Speaker/Honoraria (Ongoing)
Presenting at:
Diabetes and Nutrition - 4:15 PM, Novermber 10th
Dr. Chandarana completed medical school and Otolaryngology-Head and Neck Surgery residency training at University of Western Ontario in London, Ontario. He then pursued a two-year fellowship in Head and Neck Cancer Surgery and Microvascular Reconstruction at the University of Michigan. Concurrently, he also completed a Master’s in Public Health. In 2010, he joined the section of Otolaryngology-Head and Neck surgery (ENT), as well as the Section of Surgical Oncology at the University of Calgary and is a core member of the Head and Neck Surgery Program. From 2016 – 2022, he was the Co-Chair of the Provincial Head and Neck Cancer Tumor Team. This team oversees the delivery of head and neck cancer treatment for the province of Alberta. In 2022, Dr. Chandarana was appointed city-wide Section Chief for otolaryngology-head and neck surgery, overseeing delivery of health care as it relates to otolaryngology within the city of Calgary. He was also appointed as the Alberta representative to the executive council of the Canadian Society of Otolaryngology – Head and Neck Surgery. He enjoys a busy practice focused on head and neck cancer surgery, thyroid/parathyroid surgery and reconstructive surgery. His research focus includes clinical outcomes and health services research in head and neck surgery and evaluating practice pattern variation in the management of thyroid cancer. He is also the site co-PI for a national multi-centre active surveillance trial for low-risk papillary thyroid cancer.
Participants should be aware of the following financial/non-financial relationships:
Shamir Chandarana MD, MSc, FRCSC: Nothing to disclose
Presenting at:
Thyroid Cancer: Controversies in RAI Dosing and Primary Surveillance - 4:15 PM, November 10th
Stephanie graduated from St. Francis Xavier University with a Bachelor of Science in Human Nutrition, followed by a dietetic internship with the Capital Health internship program in Halifax, Nova Scotia. She started working as an ambulatory dietitian in chronic disease management right after graduation, and received a full-time position in the Calgary adult bariatric specialty clinic a year later. She worked in the bariatric clinic for five years prior to beginning her role as the Nutrition Services Provincial Practice Lead for Obesity and Chronic Disease in Alberta Health Services.
Participants should be aware of the following financial/non-financial relationships:
Stephanie Cameron RD: Nothing to disclose
Presenting at:
Diabetes and Bariatric Surgery - 4:15 PM, November 11th
Dr. Pedersen has a busy practice at the C-ENDO Diabetes and Endocrinology Clinic in Calgary. She is involved extensively in clinical research for diabetes and obesity as principal and/or national lead investigator. She was a member of the Expert Committee for the 2018 Diabetes Canada Clinical Practice Guidelines, and the lead author of the Pharmacotherapy chapter on the 2020 Canadian Obesity Guidelines. Dr. Pedersen has become a leading voice on how to treat obesity, metabolic syndrome and diabetes, and educates health-care professionals globally. She has a public information website about weight management and diabetes: www.drsue.ca.
Participants should be aware of the following financial/non-financial relationships:
Sue D. Pedersen MD, FRCPC, DABOM: AstraZeneca: Advisory Board (Ongoing); AstraZeneca: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Bausch Health: Advisory Board (Ongoing); Bausch Health: Consultant (Ongoing); Bausch Health: Speaker/Honoraria (Ongoing); bayer: Advisory Board (Ongoing); bayer: Consultant (Ongoing); bayer: Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Advisory Board (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Boehringer-Ingelheim: Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing)|Dexcom Canada: Consultant (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Eli Lilly: Advisory Board (Ongoing); Eli Lilly: Consultant (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing); HLS Therapeutics: Consultant (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Janssen: Consultant (Ongoing); Janssen: Speaker/Honoraria (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); novo nordisk: Advisory Board (Ongoing); novo nordisk: Consultant (Ongoing); novo nordisk: Grant/Research Support (Ongoing); novo nordisk: Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing); Pfizer: Consultant (Ongoing); Pfizer: Speaker/Honoraria (Ongoing)
Presenting at:
Pharmacological Management of Obesity in Diabetes - 2:45 PM, November 10th
Straight to the Source: Early Glucose Control AND Weight Reduction with dual GIP/GLP-1 receptor agonism in people with T2D - 7:00 AM, November 11th
Dr. Shepherd is a clinical health psychologist at Nova Scotia Health in Halifax, NS. Her PhD is from Simon Fraser University in Burnaby, BC. In her clinical work, she specializes in chronic disease self-management with patients with various chronic diseases, including diabetes, inflammatory bowel disease, and obesity. She is a part-time faculty member in the Psychology Department at Mount Saint Vincent University, and also provides training to health-care providers in behaviour change counselling skills. Her interests include chronic disease management and disease-based distress, health behaviour change, and stress and coping.
Participants should be aware of the following financial/non-financial relationships:
Tiffany Shepherd PhD: Dalhousie University Faculty of Medicine: Speaker/Honoraria (Terminated); Ellerca Health Corp.: Consultant (Terminated); Novo Nordisk Canada Inc.: Consultant (Ongoing); Takeda Canada: Speaker/Honoraria (Terminated)
Presenting at:
Diabetes and Mental Health - 10:15 AM, November 10th
Dr. Tang is Associate Professor in the Division of Endocrinology at the University of British Columbia, a Michael Smith Health Professional Investigator, and one of the few registered clinical psychologists in Canada with an expertise in type 1 diabetes (T1D). She received her A.B. from Duke University; PhD at the University of Vermont; and completed a postdoctoral fellowship at Mount Sinai School of Medicine. She has over 22 years of experience conducting diabetes translational research in high-risk and medically underserved populations. Her research focuses on developing, implementing and evaluating culturally-responsive, low-cost and sustainable models to improve long-term diabetes-related health outcomes. She has been awarded grants from the International Diabetes Federation, VGH-UBC Hospital Foundation, Vancouver Foundation, Diabetes Canada, Lawson Foundation, MSFHR, Sun-Life Financial, and NIH. Her current research investigation (funded by JDRF Canada, Brain Canada, and JDRF International) is a randomized controlled trial of T1D REACHOUT, a virtual care platform that delivers peer-led mental health support to adults with T1D living in rural and remote communities in British Columbia. REACHOUT will be translated to children, teens and adolescents with T1D, as well as their parents. Finally, Dr. Tang founded the T1D Huddle, a grass roots organization that provides free mental health and peer support for adults with T1D.
Participants should be aware of the following financial/non-financial relationships:
Tricia S. Tang PhD, RPsych: Nothing to disclose
Presenting at:
Diabetes and Mental Health - 10:15 AM, November 10th
Trish graduated from the University of Manitoba with a Bachelor of Science in Pharmacy in 2000 and has worked in community pharmacy since that time. She is currently Pharmacy Manager with an independent pharmacy in Calgary, as well as a diabetes educator with the interprofessional clinic, LMC Endocrinology Calgary. She is an advocate for positive change within the profession and a mentor for fellow pharmacists and pharmacy students.
Participants should be aware of the following financial/non-financial relationships:
Trish Molberg BScPharm, CDE, CRE, CTE: Abbott Canada: Speaker/Honoraria (Terminated); Dexcom Canada: Board Member (Ongoing); Eli Lilly: Advisory Board (Terminated); Pear Healthcare Solutions: Speaker/Honoraria (Terminated)
Presenting at:
Pharmacological Management of Obesity in Diabetes - 2:45 PM, November 10th
Dr. Lega is a Clinician Scientist at Women's College Research Institute, a Staff Endocrinologist at Women's College Hospital, an Assistant Professor at the University of Toronto and an Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES). Dr. Lega's main area of research uses ICES databases to better understand patterns and risk of diabetes overtreatment in older adults. Along with a multi-disciplinary team of pharmacists and scientists, she is planning an interventional study to improve diabetes deintensification in nursing homes in Ontario. Dr. Lega has published over 30 peer-reviewed papers, and her current research is funded by CIHR. She currently leads the update to the Hypoglycemia chapter for the Diabetes Canada Clinical Practice Guidelines, and is a National Consulting Editor for the Canadian Journal of Diabetes.
Participants should be aware of the following financial/non-financial relationships:
Iliana C. Lega MD, MSc, FRCPC: Nothing to disclose
Presenting at:
Under-recognized complications of diabetes - 2:45 PM, November 10th
CPG Update: New Remission - 1:15 PM, November 11th
Dr. Kahaly holds the rank of Professor of Medicine and Endocrinology/Metabolism at the Johannes Gutenberg University (JGU) Medical Center in Mainz, Germany. As senior physician, Dr. Kahaly directs the endocrine and thyroid autoimmunity program at the outpatient clinic and chairs the referral expert OR-PHAN center for Graves’ orbitopathy and autoimmune polyendocrinopathy. Dr. Kahaly directs the referral accredited and certified academic JGU Thyroid Laboratory and has authored 315 original papers (Lancet, NEJM, JAMA) and reviews (current citation H index 55, 13,121 citations). Dr. Kahaly is the 2022 recipient of the Jacques Genest Award of the Canadian Society of Endocrinology and Metabolism. Dr. Kahaly also is the 2019 recipient of the American College of Endocrinology Award, and the 2019 recipient of the British Thyroid Association Award. Dr. Kahaly has received further awards: British Medical Association Medical Book Award (2018); Best Reviewer Award, European Thyroid Journal (ETJ 2018); Investigator Award of the European Thyroid Association (ETA 2009); Poster prize, German Endocrine Society (2009); Research program of the German Endocrine Society (2006 & 2008); and Poster prize, German Society of Internal Medicine (2006 and 2008). Dr. Kahaly is Editor of the textbook DeGroot’ Endocrinology (eighth Ed.). He served from 2015-2019 as Editor of the Journal of Clinical Endocrinology & Metabolism. In the years 2009-2012, he was Associate Editor of the journal Thyroid, the official journal of the American Thyroid Association (ATA). Dr. Kahaly is also a member of the Editorial Board of the ETJ. Further, he was a member of the scientific program-organizing committee of the 2020 International Thyroid Congress, Xian, China, as well as of the 2020 spring meeting of the ATA. Finally, Dr. Kahaly is a member of the Publication Core Committee of the American Endocrine Society (2020-2023). Dr. Kahaly served as Treasurer and Principal Officer of the Executive Committee of the ETA between 2007 and 2016. Since 2000, he has also served on numerous ATA committees. Further, Dr. Kahaly served as Treasurer and Principal Officer of the European Group on Graves’ orbitopathy (EUGOGO) 2004-2021. In the years 2005-2011, he was a member of the Executive Committee of the German Thyroid Board.
Participants should be aware of the following financial/non-financial relationships:
George J. Kahaly MD, PhD: Horizon Therapeutics: Grant/Research Support (Ongoing); Immunovant: Consultant (Ongoing); Immunovant: Grant/Research Support (Ongoing); Merck: Consultant (Ongoing); Merck: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Novartis: Grant/Research Support (Ongoing); Quidel: Consultant (Ongoing); Quidel: Grant/Research Support (Ongoing); Sling Therapeutics: Consultant (Ongoing); Sling Therapeutics: Grant/Research Support (Ongoing)
Presenting at:
Collaborative Management of Graves' Ophthamology and New Treatment Approaches - 2:45 PM, November 10th
Dr. Robinson doesn’t like long introductions! He is a general adult psychiatrist from London, Ontario. He is a slow learner, having worked in general hospitals for 22 years before discovering what a statutory holiday was actually supposed to be. A clerical error led to him being a former Psychiatry Residency Training Director and Assistant Undergraduate Director at Western University. Dr. Robinson has written many textbooks with Rapid Psychler Press. His hobbies include driving rally cars (including three Targa Newfoundland events) and photography, and he regularly deflects shots into his own net during recreational hockey games. He is currently completing his three-peat as the lead author for the Mental Health chapter in the Diabetes Canada Clinical Practice Guidelines.
Participants should be aware of the following financial/non-financial relationships:
Dave Robinson MD, FRCPC, DLFAPA, FCPA: AbbVie: Advisory Board (Ongoing); AbbVie: Committee/Planning Member (Ongoing); AbbVie: Speaker/Honoraria (Ongoing); Allergan: Advisory Board (Ongoing)|Allergan: Committee/Planning Member (Ongoing); Allergan: Speaker/Honoraria (Ongoing); Eisai: Advisory Board (Ongoing); Eisai: Committee/Planning Member (Ongoing); Eisai: Speaker/Honoraria (Ongoing); Indivior: Advisory Board (Ongoing); Indivior: Committee/Planning Member (Ongoing); Indivior: Consultant (Ongoing); Indivior: Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Janssen: Committee/Planning Member (Ongoing); Janssen: Speaker/Honoraria (Ongoing); Lundbeck: Speaker/Honoraria (Ongoing); Master Clinician Alliance: Advisory Board (Ongoing); Master Clinician Alliance: Board Member (Ongoing); Master Clinician Alliance: Committee/Planning Member (Ongoing); Master Clinician Alliance: Consultant (Ongoing); Master Clinician Alliance: Grant/Research Support (Ongoing); Master Clinician Alliance: Speaker/Honoraria (Ongoing); Otsuka: Advisory Board (Ongoing); Otsuka: Committee/Planning Member (Ongoing); Otsuka: Speaker/Honoraria (Ongoing); Sunovion: Advisory Board (Ongoing); Sunovion: Speaker/Honoraria (Ongoing)
Presenting at:
Diabetes and Mental Health - 10:15 AM, November 10th
Dr. Sherifali is an Associate Professor in the School of Nursing at McMaster University and the inaugural holder of the Heather M. Arthur Population Health Research Institute, Hamilton Health Sciences Chair in Inter-Professional Health Research. Over the past decade, her research has focused on co-designing, evaluating and implementing diabetes interventions to support patients and health-care providers impacted by diabetes, specifically by exploring the role of health coaching through telephone and technology-enabled community-based studies, and evidence syntheses. Dr. Sherifali is also the Lead of the McMaster Evidence Review & Synthesis Team (MERST). MERST produces high-quality systematic reviews/meta-analyses which are the bedrock of evidence-based health care. Her team has produced evidence syntheses and guidelines to support informed decision-making for health-care providers and decision-makers, including the Public Health Agency of Canada, the American Heart Association, the Canadian Cardiovascular Society and Diabetes Canada.
Participants should be aware of the following financial/non-financial relationships:
Diana Sherifali RN, BScN, PhD, CDE: Nothing to disclose
Presenting at:
Role of Patient-Oriented Research in Developing New Models of Care - 10:15 AM, November 10th
Dr. MacKay is an Assistant Professor of Nutrition and Chronic Disease in the Department of Food and Human Nutritional Sciences and the Department of Internal Medicine Section Endocrinology at the University of Manitoba. He has a background in Human Nutritional Sciences, with training and experience in clinical trials and patient-oriented research. His work concentrates primarily on type 2 diabetes and chronic kidney disease. He is a person who lives with type 1 diabetes and participates in various type 1 diabetes research projects as both a researcher and a patient partner. He currently manages his diabetes with the help of an OpenAPS closed loop pump system.
Participants should be aware of the following financial/non-financial relationships:
Dylan MacKay PhD: Chronic Disease Innovation Center at Seven Oaks Hospital: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Diabetes Canada: Advisory Board (Ongoing); Food Fare Grocery Stores: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); NorWest Community Health Co-op: Grant/Research Support (Ongoing); NorWest Community Health Co-op: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Pepsico: Grant/Research Support (Ongoing); Save-On Foods: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); The Kidney Foundation of Canada: Grant/Research Support (Ongoing)
Presenting at:
CPG Update: New Remission - 1:15 PM, November 11th
Dr. Gucciardi is full professor in the School of Nutrition at Toronto Metropolitan University. She has an undergraduate degree in Nutritional Sciences from Toronto Metropolitan University, a Masters degree in Community Health and Epidemiology from the Department of Public Health Sciences and a PhD from the Institute of Medical Sciences, both from the University of Toronto. Dr. Gucciardi's program of research addresses the current challenges of delivering effective self-management support to the increasing population of Canadians with diabetes, or at risk for diabetes. She primarily focuses on diabetes self-management practices, the participation and delivery of diabetes self-management education and support programs, and the use, coordination and integration of diabetes management resources and services across the health-care system. She also examines the intersection of food insecurity and diabetes self-management, developing screening tools and other strategies for care providers to better support self-management among this vulnerable population. Dr. Gucciardi adopts an interdisciplinary approach and uses mixed methodologies in her research.
Participants should be aware of the following financial/non-financial relationships:
Enza Gucciardi Bsc, MHsc, PhD: Nothing to disclose
Presenting at:
Putting Theory into Action: Supporting Behaviour Change in Individuals at Risk or living with Type 2 Diabetes - 4:14 PM, Novermber 10th
Dr. Bakris is a Nephrologist/Clinical Pharmacologist and Certified Hypertension Specialist trained at the Mayo Clinic and the University of Chicago Medicine. He is a Professor of Medicine and Director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine. He has published over 900 peer-reviewed articles and book chapters in the areas of diabetic kidney disease, hypertension and nephropathy progression. He is the editor or co-editor of 24 books in the areas of diabetic kidney disease progression and hypertension. Additionally, he is the co-editor of the 3rd and new 4th editions of Hypertension: A Companion to Braunwald’s Heart Disease. He has served on the FDA Cardiorenal Advisory Board for 10 years and has been a consultant to CMS for four years. He has also served on many national guideline committees, including the Joint National Committee JNC 7 writing group, the ADA Clinical Practice and Laboratory Guideline Committee, as well as the KDOQI guidelines.
Participants should be aware of the following financial/non-financial relationships:
George Bakris FAHA, FASN: AstraZeneca: Consultant (Ongoing); Bayer: Advisory Board (Ongoing); Bayer: Consultant (Ongoing); Bayer: Grant/Research Support (Ongoing); Ionis: Consultant (Ongoing); Vifor: Consultant (Ongoing)
Presenting at:
Chronic Kidney Disease in Diabetes: Update - 10:15 AM, November 11th
After studying for a PhD in Bristol with Dick Denton FRS on mitochondrial Ca2 signalling, Dr. Rutter subsequently worked on the pancreatic β-cell as an MRC travelling Fellow with Claes Wollheim in Geneva. There, working collaboratively with Tullio Pozzan and Rosario Rizzuto in Padua, he established new approaches to exploring the control of insulin release at the single cell level through the use of recombinant target probes and other techniques. He then returned to Bristol, becoming a full Professor of Biochemistry in 2002, moved to Imperial College in 2006 and moved to Université de Montréal in 2021. Hid current research is supported by Wellcome Trust Senior Investigator and Royal Society Wolfson Merit Awards, by UK Research Council and Diabetes UK grants, as well as by the European Commission Innovative Medicines Initiative in Diabetes (IMIDIA).
Participants should be aware of the following financial/non-financial relationships:
Guy Rutter PhD: Sun Pharmaceuticals: Consultant (Ongoing); Sun Pharmaceuticals: Grant/Research Support (Ongoing)
Presenting at:
Novel mechanisms of insulin secretion - 10:15 AM, Novermber 10th
Dr. Witteman is the Canada Research Chair in Human-Centred Digital Health and a Full Professor in the Department of Family & Emergency Medicine, Université Laval in Quebec City. Dr. Witteman is a scientist in the VITAM Research Centre for Sustainable Health, the Research Centre of the CHU de Québec-Université Laval, and an Affiliate Investigator at the Ottawa Hospital Research Institute in Ottawa. With an interdisciplinary background in human factors engineering and social sciences, her research is about how we can achieve human-centredness in health-related domains, including a focus on how best to adapt digital health technology to people rather than expecting people to adapt to technology. She specializes in human-computer interaction in health education, risk communication and decision making, including design methods and system changes to support inclusive user-, human- and patient-centredness. Her work as Principal Investigator has been funded by the Fonds de recherche du Québec – Santé (FRQS), the Patient-Centered Outcomes Research Institute (PCORI, United States), the Canada Foundation for Innovation (CFI), the Canadian Immunization Research Network (CIRN), Sentinelle Nord, and the Canadian Institutes of Health Research (CIHR). She has lived with type 1 diabetes since age 7.
Participants should be aware of the following financial/non-financial relationships:
Holly Witteman PhD: Nothing to disclose
Presenting at:
Role of Patient-Oriented Research in Developing New Models of Care - 10:15 AM, November 10th
Annabell has been a practicing Registered Nurse for 25 years, during which time she acquired her Master’s in Nursing. She has been working as a Certified Diabetes Educator and a Certified Pump Trainer for the last 16 years, and she practices in downtown Toronto at St. Michael's Hospital. She and her colleagues (educators and endocrinologists) use a team approach to manage the diverse population there. Their centre provides services to individuals 18 years and older with type 1 and type 2 diabetes. They also have a specialized clinic for young adults aged 18-24 years, and also one for gestational diabetes. Their aim is to empower individuals to be stewards of their own health to achieve the best possible outcomes.
Participants should be aware of the following financial/non-financial relationships:
Annabell Hall, RN MN CDE: Nothing to disclose
Presenting at:
Continuous Glucose Monitoring — Practical Approaches - 1:30 PM, November 9th
Leigh has been working as a certified diabetes nurse educator for over 25 years in a variety of settings, with a diverse population of patients and health-care providers. As part of the Sunnybrook Academic Family Health team, she has led the expansion of the diabetes program and interprofessional education. She continues to be involved in local and provincial committees to improve care of people with diabetes. Leigh is an instructor of Health Leadership and Learning Network in the faculty of Health at York University.
Participants should be aware of the following financial/non-financial relationships:
Leigh Caplan RN, BSc, MA, CDE: Abbott Canada: Advisory Board (Ongoing); Abbott Canada: Speaker/Honoraria (Ongoing); Becton Dickinson and Company: Speaker/Honoraria (Ongoing)
Presenting at:
To Pump or Not to Pump: Welcome to the World of Insulin Pumping - 1:30 PM, November 11th
promoted to Clinical Professor of Medicine. Within the Division of Nephrology, Dr. Girard focuses on clinical immunology and infectious diseases in chronic kidney disease patients. He is the medical director of the Glomerulonephritis Clinic and Apheresis. He has developed several specialty clinics for the treatment of rare diseases, including clinics for the treatment of complement mediated disease, Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease. His work in this area was recognized with the Dr. John Conly award for innovation. Recently, he became the program director of the newly created GN Fellowship program, which has its first trainee, who started training July 2022. Additionally, he is the co-chair of the Glomerulonephritis and Diabetic Kidney Disease sub-committees of the Medicine Strategic Clinical Network for Alberta Health. He is heavily involved in clinical trials. He has several peer-reviewed publications, including a co-authored publication in the New England Journal of Medicine. Furthermore, he is a member of CAN-VASC and is a co-author on the most recent Canadian ANCA Vasculitis guidelines. Dr. Girard is also a member of the Canadian Apheresis Group, as well as the Executive Planning Group. As part of his role within CAG, Dr. Girard also serves on the TMA/TTP working groups. Dr. Girard has a strong commitment to education and has won numerous awards for his teaching contributions at all levels of medical training. He has been faculty on numerous national CME presentations with a focus on diabetes and chronic kidney disease. He was also invited by Diabetes Canada to author a review on SGLT2i and the kidney.
Participants should be aware of the following financial/non-financial relationships:
Louis Girard MD, MBT, FRCPC: AstraZeneca: Advisory Board (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Bayer Inc.: Advisory Board (Ongoing); Bayer Inc.: Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Advisory Board (Ongoing)|Boehringer-Ingelheim: Speaker/Honoraria (Ongoing); Janssen: Advisory Board (Ongoing); Janssen: Speaker/Honoraria (Ongoing)
Presenting at:
Chronic Kidney Disease in Diabetes: Update - 10:15 AM, November 11th
Dr. Harris is a Professor in the Department of Family Medicine, with cross appointments in the Departments of Epidemiology & Biostatistics and Division of Endocrinology & Metabolism, of the Schulich School of Medicine & Dentistry at Western University. Dr. Harris is also a Research Scientist at the Lawson Health Research Institute. He was reappointed to a third term in 2019 to the position of the Diabetes Canada Chair in Diabetes Management. Dr. Harris is also the lead physician and Medical Director at the Primary Care Diabetes Support Program (PCDSP) at St. Joseph’s Health Care, London, ON – an integrated team-based diabetes clinic for disenfranchised and marginalized populations, which he founded in 2007. Dr. Harris’s research program focuses on three priority areas: (1) diabetes research with Indigenous Peoples; (2) hypoglycemia research; and (3) clinical trials. Dr. Harris has published over 300 articles in peer-reviewed journals and participated extensively in clinical practice guideline development, including serving as Chair of the Canadian Diabetes Association clinical practice guidelines committee. He is the recipient of the Ontario Ministry of Heath Career Scientist award, the Dr. Gerald S. Wong Service Award of Daibetes Canada, the Hellmuth Prize for Achievement in Research at Western University, and is a Fellow in the Canadian Academy of Health Sciences. On July 1, 2015, Dr. Harris was appointed to the Order of Canada for his contributions to the development of strategies to manage and reduce diabetes in Aboriginal communities and other vulnerable populations.
Participants should be aware of the following financial/non-financial relationships:
Stewart B. Harris CM, MD, MPH, FCFP, FACPM: Nothing to disclose
Presenting at:
Hypoglycemia: Risk Considerations and New Strategies - 8:00 AM, Novermber 12th
Jill is a Registered Dietitian and Certified Diabetes Educator at the Sunnybrook Diabetes Education Centre (SUNDEC) at Sunnybrook Health Sciences Centre in Toronto. She has worked in the area of diabetes education for over 25 years. Jill enjoys working with clients to help make living with diabetes easier. Jill is a tutor in the University of Toronto Medical School’s Community, Population and Public Health (CPPH) course. She enjoys teaching with medical students and dietetic interns. Outside of work, Jill enjoys spending time with family and friends and doing outdoor activities, such as hiking, tennis, biking and skiing.
Participants should be aware of the following financial/non-financial relationships:
Jill Zweig RD CDE: Nothing to disclose
Presenting at:
To Pump or Not to Pump: Welcome to the World of Insulin Pumping - 1:30 PM, November 11th
Dr. Gagnon is an adult endocrinologist working at CHU de Québec-Université Laval, an Associate Professor in the Department of Medicine at Université Laval, and a clinician-researcher scholar of the Fonds de recherche du Québec-Santé (FRQ-S). After completing residency training in adult endocrinology at Université de Sherbrooke in 2006, she undertook a three-year clinical and research fellowship in metabolic bone diseases and phosphocalcic metabolism in Melbourne, Australia, under the supervision of Prof. Peter Ebeling and Prof. Robin Daly. Her research focuses on the impact of obesity, diabetes and their treatments (in particular bariatric surgery) on bone health. She has received funding from Diabetes Canada, Diabète Québec, and the Canadian Institutes of Health Research and published over 50 articles in peer-reviewed journals. She has been awarded the 2019 Jean-Davignon Young Investigator Award from the Cardiometabolic, diabetes and obesity FRQ-S network, the 2017 research prize of the Fédération des médecins spécialistes du Québec, and a New Investigator Award at the International Symposium on the Nutritional Aspects of Osteoporosis in 2015. She is Vice Chair of the Scientific Advisory Council of Osteoporosis Canada. She is also involved in the upcoming international guidelines on vitamin D supplementation after bariatric surgery.
Participants should be aware of the following financial/non-financial relationships:
Claudia Gagnon MD: Nothing to disclose
Presenting at:
Under-recognized complications of diabetes - 2:45 PM, Novermber 10th Spotlight on Up and Coming Scientists - 12:15 PM, Novermber 11th
Dr. Drucker is a Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, and a Professor of Medicine at the University of Toronto. His laboratory studies the molecular biology and physiology and translational science of the glucagon-like peptides, These studies have supported the development of multiple different classes of medicine for the treatment of metabolic disorders.
Participants should be aware of the following financial/non-financial relationships:
Daniel Drucker MD: Amgen: Advisory Board (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); Kallyope: Advisory Board (Ongoing); Merck: Advisory Board (Ongoing); Novo Nordisk A/S: Advisory Board (Ongoing); Novo Nordisk A/S: Grant/Research Support (Ongoing); Pfizer: Advisory Board (Ongoing); Pfizer: Grant/Research Support (Ongoing)
Dr. Samuels is the Medical Director of the Centre for Sleep & Human Performance and The Sleep Institute in Calgary, Alberta, Canada. He is a Diplomat of the American Board of Sleep Medicine and a member of the College of Family Physicians of Canada. He is a member of the Sleep Medicine Advisory Committee of the College of Physicians and Surgeons of Alberta. Dr. Samuels is a Clinical Assistant Professor of Medicine in the Cummings School of Medicine, Adjunct Professor in the Faculty of Kinesiology, and a member of the Institute of Population Health at the University of Calgary. Dr. Samuels serves on the Executive Board of the Canadian Sleep Society as the Past President (2017-2019). Dr. Samuels’ research focus is the relationship of sleep to recovery, training and performance in elite Olympic athletes, and he is the Principal Investigator of the development and validation of the Athlete Sleep Screening Questionnaire. He has also served as the Principal Investigator of research projects exploring the health effects of sleep disturbance associated with shift work in law enforcement officers for the Calgary Police Service and the Royal Canadian Mounted Police.
Participants should be aware of the following financial/non-financial relationships:
Charles Samuels MD, CCFP, DABSM: Athlete Sleep Screening Questionnaire ©: Grant/Research Support (Ongoing); Athlete Sleep Screening Questionnaire ©: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Centre for Sleep & Human Performance: Employment (Ongoing); Centre for Sleep & Human Performance: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cerebra Health Ltd.: Advisory Board (Ongoing)|Cerebra Health Ltd.: Board Member (Ongoing); Eisai Pharmaceuticals: Advisory Board (Ongoing); Eisai Pharmaceuticals: Consultant (Ongoing); Eisai Pharmaceuticals: Speaker/Honoraria (Ongoing); FitGMR Ltd.: Advisory Board (Ongoing); FitGMR Ltd.: Consultant (Ongoing); FitGMR Ltd.: Speaker/Honoraria (Ongoing); Jazz Pharmaceuticals: Advisory Board (Ongoing); Jazz Pharmaceuticals: Consultant (Ongoing); Jazz Pharmaceuticals: Speaker/Honoraria (Ongoing); Online Fatigue Management Training Program for Law Enforcement ©: Grant/Research Support (Ongoing); Online Fatigue Management Training Program for Law Enforcement ©: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Paladin Pharmaceuticals: Advisory Board (Ongoing); Paladin Pharmaceuticals: Consultant (Ongoing); Paladin Pharmaceuticals: Speaker/Honoraria (Ongoing); Red Bull International: Consultant (Ongoing); Red Bull International: Speaker/Honoraria (Ongoing)|Royal Canadian Mounted Police: Consultant (Ongoing); Royal Canadian Mounted Police: Grant/Research Support (Ongoing); Royal Canadian Mounted Police: Speaker/Honoraria (Ongoing); Sunovion Pharmaceuticals: Advisory Board (Ongoing); Sunovion Pharmaceuticals: Consultant (Ongoing); Sunovion Pharmaceuticals: Speaker/Honoraria (Ongoing); The Sleep Institute: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Presenting at:
Sleep, Circadian Rhythms and Metabolic Disease: What you Need to Know and How you make it Happen! - 2:45PM, November 11th
Dr. Cheng is an endocrinologist at Trillium Health Partners and Unity Health Toronto and an Associate Professor at the University of Toronto. She has been involved with the development of the Diabetes Canada clinical practice guidelines since 2003 and served as Chair for the 2013 version. She is serving on the Editorial Board for the Canadian Journal of Diabetes and is immediate Past-Chair of the Professional Section of Diabetes Canada. She is also serving as Chair of the Scientific Planning Committee for the 2023 and 2024 American Diabetes Association annual scientific meetings, which is the largest international diabetes conference in the world. In recognition of her contribution to the diabetes community, she has received the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada. She is also the creator of The Med Ed Pledge – an initiative to increase Diversity & Inclusion in continuing medical education (www.theMedEdPledge.com).
Participants should be aware of the following financial/non-financial relationships:
Alice YY. Cheng MD, FRCPC: Abbott: Advisory Board (Ongoing); Abbott: Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); AstraZeneca: Advisory Board (Ongoing); AstraZeneca: Speaker/Honoraria (Ongoing); Bausch Health: Speaker/Honoraria (Ongoing); bayer: Advisory Board (Ongoing); bayer: Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Advisory Board (Ongoing); Boehringer-Ingelheim: Speaker/Honoraria (Ongoing); Dexcom Canada: Consultant (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Eli Lilly: Advisory Board (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); GlaxoSmithKline: Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); Insulet: Advisory Board (Ongoing); Insulet: Speaker/Honoraria (Ongoing); Janssen: Speaker/Honoraria (Ongoing); Medtronic: Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Novo Nordisk A/S: Advisory Board (Ongoing); Novo Nordisk A/S: Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing); Sanofi: Speaker/Honoraria (Ongoing); Shire (Takeda): Advisory Board (Ongoing)
Presenting at:
Chronic Kidney Disease in Diabetes: Update - 10:15 AM, November 11th
Dr. Pepper was recruited to the Department of Surgery, in the Division of Surgical Research at the University of Alberta, as an Assistant Professor in 2018. His laboratory in the Alberta Diabetes Institute examines the underlying mechanisms that govern pancreatic beta cell survival and function, with the ultimate goal of developing and refining islet replacement therapies that could become a universal treatment for a broader range of people living with type 1 diabetes. His studies range from in vitro models to clinical transplants, including: 1) Developing cell transplant technologies without immunosuppression. 2) Improving function of pancreatic beta cell grafts. 3) Translating alternative beta cell sources into an unlimited supply of insulin-producing cells. He has published >40 manuscripts and four book chapters related to islet biology, immunology and beta cell transplantation. Recently, Dr. Pepper was awarded a Canadian Research Chair in Cell Therapies for Diabetes and was previously awarded the JDRF - International Career Development Award. His lab has received funding from the JDRF, MITACS, CIHR, CFI-JELF, Stem Cell Network, Alberta Innovates, New Frontiers in Research Fund, Alberta Diabetes Foundation, University Hospital Foundation and the Canadian National Transplant Research Program. Dr. Pepper is a member of the Canadian Islet Research and Training Network (CIRTN) - Mentorship Committee and Stem Cell Network (SCN) - Teaching and Education Committee.
Participants should be aware of the following financial/non-financial relationships:
Andrew R. Pepper PhD: Encellin: Consultant (Ongoing)
Presenting at:
Stem cell therapies for diabetes: What’s new and what’s on the horizon? - 10:15 AM, November 11th
Dr. Morgenthau has a Bachelor of Science from Toronto Metropolitan University, a Master of Science from the University of Calgary, and an MD from New York Medical College. He completed his core Internal Medicine training at Dalhousie University and his Endocrinology and Metabolism training at the University of Toronto. Throughout his training, he has developed an interest/focus in clinical genetics and endocrinology. Building on this interest, he is currently pursuing additional training as a fellow within the division of clinical and metabolic genetics at the University of Toronto, with a focus on endocrine genetics.
Participants should be aware of the following financial/non-financial relationships:
Ari Morgenthau MD, MSc, FRCPC: Global Genes: Consultant (Ongoing)
Presenting at:
Adrenal Hypertension: Differential Diagnosis, Monitoring & Surveillance - 2:45 PM, November 11th
Dr. Holmes earned his undergraduate degree in Chemical Physics from the University of Toronto. He went to medical school at the University of British Columbia (UBC), where he also did his residency in Medical Biochemistry. He is a Clinical Professor of Pathology and Laboratory Medicine at UBC and Head and Medical Director of the Department of Pathology and Laboratory Medicine at St. Paul’s Hospital in Vancouver. His interests include clinical endocrinology, with a focus on secondary hypertension, lipidology, clinical mass spectrometry, and data science in application to data automation, visualization and clinical utilization.
Participants should be aware of the following financial/non-financial relationships:
Daniel T. Holmes MD, FRCPC: Americal Association of Clinical Chemistry: Board Member (Ongoing); Americal Association of Clinical Chemistry: Committee/Planning Member (Ongoing); Americal Association of Clinical Chemistry: Speaker/Honoraria (Ongoing); MSACL: Board Member (Ongoing); MSACL: Committee/Planning Member (Ongoing); MSACL: Speaker/Honoraria (Ongoing); SCIEX: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)|Waters: Advisory Board (Terminated)
Presenting at:
Adrenal Hypertension: Differential Diagnosis, Monitoring & Surveillance - 2:45 PM, November 11th
Dr. Bajaj is an endocrinologist and Director of Late-Phase Research at LMC Healthcare. Dr Bajaj completed his clinical endocrinology fellowship at the Cleveland Clinic (Ohio, USA). Dr Bajaj’s completed his medical education at University of Delhi, India, following which he attained a Master of Public Health (Epidemiology) degree at State University of New York in Albany (New York, USA). Dr. Bajaj is a research associate at Mount Sinai Hospital, Toronto, and an adjunct lecturer at McMaster University, Hamilton. He has co-authored publications in key medical journals in the fields of diabetes prevention and management, obesity, and cardiovascular risk assessment. He is the Principal Investigator of the Canadian Diabetes Prevention Program, a nationwide collaborative effort between LMC, Diabetes Canada and the Public Health Agency of Canada. Dr. Bajaj currently serves Diabetes Canada on the Professional Section National Executive and as the Chair of the Clinical Practice Guidelines (CPG).
Participants should be aware of the following financial/non-financial relationships:
Harpreet Singh Bajaj MD, MPH, FACE: Amgen: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Boehringer Ingelheim: Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); novo nordisk: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Sanofi: Grant/Research Support (Terminated); Tricida: Grant/Research Support (Ongoing)
Presenting at:
CPG Update: New Remission - 1:15 PM, November 11th
Dr. Bouteaud is an ob/gyn at CHUM. She studied medicine at Mcgill University and went on to do her residency at Université de Montréal. Dr. Bouteaud pursued a fellowship in mature women's health at Mount Sinai Hospital and the University of Toronto, along with a research fellowship in quality improvement. She has developed unique expertise in early surgical menopause in women with high risk genetic mutations, like BRCA. In 2021, she received the young trainee award from the North American Menopause Society, along with a Royal College of Physicians and Surgeons of Canada bridging grant and a research grant from the Canadian Menopause Society.
Participants should be aware of the following financial/non-financial relationships:
Jeanne Bouteaud MD, MSc: Nothing to disclose
Dr. Rocheleau earned a PhD in Biochemistry from Western University for the development of advanced quantitative live cell imaging. Subsequent postdoctoral studies at Vanderbilt University Medical Center provided his introduction to islet biology, where he successfully coupled various biophysical and bioengineering tools to assay islet metabolism and insulin secretion. His lab at the Toronto General Hospital Research Institute and University of Toronto specializes in the development of genetically encoded sensors (‘Apollo sensors’) and islet-on-a-chip microfluidic devices to assay glucose-stimulated metabolism and insulin secretion from living pancreatic islets. These tools are being used to address the mechanisms underlying first phase insulin secretion, which is lost at the earliest stages of type 2 diabetes. Dr. Rocheleau was previously awarded the Percy Edward Hart Professorship (2016-2020) and is presently a Senior Scientist (TGHRI) and Associate Professor (BME, UofT). Consistent with the interdisciplinarity of his research, his lab is supported by both the Natural Sciences and Engineering Research Council (NSERC) and the Canadian Institutes of Health Research (CIHR).
Participants should be aware of the following financial/non-financial relationships:
Jonathan Rocheleau PhD: Nothing to disclose
Presenting at:
Translational models systems and new tools for the study of diabetes - 10:15 AM November 11th
Kaberi Dasgupta is Professor of Medicine at McGill University and Physician Scientist and Director at the Centre for Outcomes Research and Evaluation of the Research Institute of the McGill University Health Centre. Her focus is the prevention, reversal, and management of diabetes through health behaviour change and action on social determinants. She holds grants from the CIHR, MRC, Lawson Foundation, JM McConnell Family Foundation, and the Heart and Stroke Foundation of Canada. She led the CIHR funded SMARTER trial to develop and evaluate a physician-delivered step count prescription that is integrated into Diabetes Canada clinical practice guidelines. Following her Diabetes Canada funded study study demonstrating high levels of stigma in youth with type 1 diabetes, she obtained CIHR and Diabetes Canada funding to support the now 240 strong Virtual Peer Network to support youth and young adults with type 1 diabetes. She is internationally recognized for her work demonstrating gestational diabetes to be a diabetes risk indicator not only in mothers but also for type 2 diabetes in fathers and type 1 diabetes in offspring. She has over 130 publications. Some of her former students are now scientists and physician scientists based at McGill University, University of Toronto, Harvard University, and the London School of Hygiene and Tropical Medicine, working in the areas of diabetes, epidemiology, and behavioural change.
Participants should be aware of the following financial/non-financial relationships:
Kaberi Dasgupta, MD,MSc,FRCP(C): Nothing to disclose
Presenting at:
Cardiovascular risk reduction after gestational diabetes - 10:15 AM, November 11th
Dr. Nerenberg is an Associate Professor and Clinician-Scientist at the University of Calgary working in the areas of General Internal Medicine and Obstetric Medicine. Dr. Nerenberg’s clinical and research interests focus on the prevention of cardiovascular diseases in people after common pregnancy complications, mainly gestational diabetes and the hypertensive disorders of pregnancy. Her research is supported by CIHR and Heart & Stroke’s Women’s Heart and Brain Health Mid-Career Research Chair.
Participants should be aware of the following financial/non-financial relationships:
Kara A. Nerenberg MD, MSc: Nothing to disclose
Presenting at:
Cardiovascular risk reduction after gestational diabetes - 10:15 AM, November 11th
Dr. Stewart is a Pediatric Endocrinologist working at BC Children's Hospital. She is an Associate Clinical Professor at the University of British Columbia. She is also the Program Director for the Pediatric Endocrinology and Metabolism subspecialty program at the University of British Columbia. Her focus of practice is clinical care for children with endocrinopathies and diabetes. She is also a medical educator.
Participants should be aware of the following financial/non-financial relationships:
Laura Stewart MD, FRCPC: Nothing to disclose
Presenting at:
Hormone Treatments Throughout the Lifespan and Across Genders - 10:45 AM, November 11th
Dr. Poudineh is an Assistant Professor at the University of Waterloo, Department of Electrical and Computer Engineering, and the founding director of IDEATION Lab (Integrated Devices for Early disease Awareness and Translational applicatIONs Laboratory). She received her PhD degree in Electrical Engineering from the University of Toronto in 2016. Prior to joining Waterloo, Dr. Poudineh completed postdoctoral training at the University of Toronto, and Stanford University, School of Medicine, in 2018 and 2019, respectively. Her research interests include developing biosensing approaches for diagnostic and therapeutic purposes, continuous health monitoring, and translating biomedical devices to the clinic and market. Her research has been selected as Science Translational Medicine Editor’s choice article and highlighted in the Nature News & Views. She was the recipient of the best poster award during the Micro- and Nanotechnologies for Medicine Workshop held at UCLA (July 2019). She has been also selected as an Inaugural Contributor to the Nanoscale Emerging Investigators Themed Collection. Dr. Poudineh has secured over $3 million CAD in peer-reviewed funding to support the research program at the IDEATION Lab in the short period of less than three years, including a CIHR project grant and a JDRF grant.
Participants should be aware of the following financial/non-financial relationships:
Mahla Poudineh PhD: Nothing to disclose
Presenting at:
Translational models systems and new tools for the study of diabetes - 10:15 AM November 11th
Dr. Poudineh is an Assistant Professor at the University of Waterloo, Department of Electrical and Computer Engineering, and the founding director of IDEATION Lab (Integrated Devices for Early disease Awareness and Translational applicatIONs Laboratory). She received her PhD degree in Electrical Engineering from the University of Toronto in 2016. Prior to joining Waterloo, Dr. Poudineh completed postdoctoral training at the University of Toronto, and Stanford University, School of Medicine, in 2018 and 2019, respectively. Her research interests include developing biosensing approaches for diagnostic and therapeutic purposes, continuous health monitoring, and translating biomedical devices to the clinic and market. Her research has been selected as Science Translational Medicine Editor’s choice article and highlighted in the Nature News & Views. She was the recipient of the best poster award during the Micro- and Nanotechnologies for Medicine Workshop held at UCLA (July 2019). She has been also selected as an Inaugural Contributor to the Nanoscale Emerging Investigators Themed Collection. Dr. Poudineh has secured over $3 million CAD in peer-reviewed funding to support the research program at the IDEATION Lab in the short period of less than three years, including a CIHR project grant and a JDRF grant.
Participants should be aware of the following financial/non-financial relationships:
Ramon Klein-Geltink PhD: Nothing to disclose
Presenting at:
Immunometabolic dysfunction in diabetes - 2:45 PM, Novermber 11th
Dr. Fung trained in Endocrinology at the University of Toronto. He is an endocrinologist at Michael Garron Hospital and is currently the head of the division. He has a special interest in providing trans care. He is actively involved in educating residents about trans care and in research projects related to trans care.
Participants should be aware of the following financial/non-financial relationships:
Raymond Fung MD, FRCPC: Nothing to disclose
Presenting at:
Hormone Treatments Throughout the Lifespan and Across Genders - 10:45 AM, November 11th
Dr. Dhanvantari (she/her) is a Research Scientist in the Metabolism & Diabetes and Imaging Programs at the Lawson Health Research Institute and Associate Professor in the Departments of Medical Biophysics and Pathology & Laboratory Medicine at Western University in London, Ontario, Canada on the Dish with One Spoon territory. Her research program focusses on the cell biology of diabetes, and she has developed novel molecular imaging tools to investigate the cellular dysfunction of pancreatic islets. She is also an Assistant Scientific Director and EDI Lead at Lawson, serves on the Ontario Hospitals Association Anti-Racism Task Force, and participates in the DEI Working Group at the World Molecular Imaging Society. Dr. Dhanvantari firmly believes that diversity drives scientific excellence, and policies must be restructured to ensure that hospital-based research truly benefits our society as a whole.
Participants should be aware of the following financial/non-financial relationships:
Savita Dhanvantari PhD: Nothing to disclose
Presenting at:
Beyond the beta cell: The other endocrine islet cells - 4:15 PM, November 11th
Dr. Tsai is an early investigator at the University of Alberta studying immunology and immunometabolism. She did her PhD in Dr. Pere Santamaria’s lab, where her thesis focused on tolerance induction in type 1 diabetes (T1D) by protective major histocompatibility complex class II (MHC II) genes, as well as with antigen specific nanoparticle-based immunotherapeutic vaccines. She then moved to Toronto and did her postdoctoral training with Dr. Daniel Winer at the University Health Network. During this time, she expanded her horizon and studied mechanisms of immune dysregulation in models of obesity-related insulin resistance. Her current research focus builds on her experiences to understand the regulation of the immune response and its connection to metabolism during chronic diseases, such as type 1 diabetes and type 2 diabetes. Using a combination of preclinical models and vaccination methodologies, her laboratory studies the role of immune and metabolic signaling in disease development and progression, and explores potential new strategies to improve protective immunity.
Participants should be aware of the following financial/non-financial relationships:
Sue Tsai PhD: Nothing to disclose
Presenting at:
Immunometabolic dysfunction in diabetes - 2:45 PM, Novermber 11th
Susie is a community pharmacist where she has applied herself as a Certified Diabetes Educator, Certified Fitter of Compression Therapy and Certified Respiratory Educator. Nationally, Susie serves on and leads several committees: with Diabetes Canada as a chapter author of the Diabetes Canada Clinical Practice Guidelines and as a member of the Dissemination and Implementation Committee; and with Wounds Canada where she serves on the Board of Directors and has co-authored Wounds Canada Best Practice Recommendations. Provincially, Susie serves on a variety of committees to effect practice and health care in our communities, such as the Health Quality Ontario, Diabetes Quality Standard Advisory Committee and the Ontario Immunization Advisory Committee. Susie is the 2020 Charles H. Best Award recipient, which is given to a health-care professional who has made a significant difference across Canada towards improving the quality of life of individuals living with diabetes; and she was awarded the 2021 Diabetes Canada Educator of the Year.
Participants should be aware of the following financial/non-financial relationships:
Susie Jin RPh, CDE, CRE: Nothing to disclose
Presenting at:
CPG Update: New Remission - 1:15 PM, November 11th
Dr. Poitout received his Doctorate in Veterinary Medicine from the École Nationale Vétérinaire d’Alfort and his PhD degree from the Université Paris 6. He completed a post-doctoral fellowship at the University of Minnesota, Minneapolis, MN. He was an INSERM scientist at the Hôtel-Dieu hospital in Paris, France and then Principal Scientist at the Pacific Northwest Research Institute and Affiliate Assistant Professor of Medicine at the University of Washington in Seattle, WA, before joining the University of Montreal in 2005. Dr. Poitout is currently Professor of Medicine at the University of Montréal and Director of Research at the Centre Hospitalier de l’Université de Montréal (CHUM). Dr. Poitout is the former Chair of the National Research Council of Diabetes Canada and of the American Diabetes Association’s Grant Review Panel, and a former member of the Board of Directors of the American Diabetes Association. He has been a member of the Editorial Boards of Diabetes and The Journal of Biological Chemistry, and Associate Editor for Diabetologia. Dr. Poitout’s research is funded by the US National Institutes of Health, the Canadian Institutes of Health Research, and the Natural Sciences and Engineering Research Council of Canada. Dr. Poitout has received several awards, including the Albert Renold Fellowship from the European Association for the Study of Diabetes, the 2003 Thomas R. Lee Career Development Award from the American Diabetes Association, and the 2009 Young Scientist Award from the Canadian Diabetes Association. He held the Canada Research Chair in Diabetes and Pancreatic Beta-Cell Function from 2006 to 2020. Dr. Poitout is a Fellow of the Canadian Academy of Health Sciences.
Participants should be aware of the following financial/non-financial relationships:
Vincent Poitout DVM, PhD: Nothing to disclose
Presenting at:
Beyond the beta cell: The other endocrine islet cells - 4:15 PM, November 11th
Dr. Imran is a Professor of Medicine in the Division of Endocrinology at Dalhousie University. He is also Director of Pituitary and Thyroid Oncology clinics at his hospital. Dr. Imran has published several key papers on neuropituitary disorders and thyroid cancer, and has also authored a book on Neuroendocrinology. He is also a keen cyclist and watercolorist, and enjoys spending time in nature.
Participants should be aware of the following financial/non-financial relationships:
Ali Imran MD: Nothing to disclose
Presenting at:
Pituitary Session: Treatment Resistant Prolactinomas; Infiltrative Diseases of the Pituitary - 9:30 AM, November 12th
Dr. Klip is a Senior Scientist in the Cell Biology Program of Toronto’s Hospital for Sick Children and a Professor of Pediatrics, Biochemistry and Physiology at the University of Toronto. For almost 40 years, she has directed studies on insulin action at the cellular and molecular levels. She was first to reveal the insulin- and exercise-dependent translocation of glucose transporters from inside the muscle to its surface. Her group’s current work focuses on mechanisms that confer insulin resistance to muscle, including engagement of the innate immune system, and on insulin and glucose interactions with microvascular cells. Dr. Klip received her PhD in Biochemistry in Mexico City, did postdoctoral training at the University of Toronto and the ETH in Zurich, and joined Toronto’s SickKids in 1980, where she was an Associate Chief of Research for 18 years and the Founding Director of the Research Training Centre. A former Editor-in-Chief of the American Journal of Physiology: Endocrinology and Metabolism, she also held the Canada Research Chair in Cell Biology of Insulin Action for 14 years. Dr. Klip is an elected fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences, she has received distinguished international awards, as well as personnel awards from the MRC/CIHR (Fellowship, Scholarship, Scientist and Distinguished Scientist) and an Honorary Doctorate from the University of Copenhagen. Dr. Klip has led advisory and review panels at the Karolinska Institute in Stockholm, the Leloir Foundation in Buenos Aires, and the University of British Columbia. She has authored over 300 original peer-reviewed papers and invited reviews, directed the research of over 50 graduate students and 40 postdoctoral fellows, and is currently the recipient of a CIHR Foundation Grant.
Participants should be aware of the following financial/non-financial relationships:
Amira Klip PhD: Nothing to disclose
Presenting at:
Molecular mechanisms of insulin signalling and resistance in obesity and diabetes - 10:45 AM, Novermber 12th
Dr. Carpentier is the Canada Research Chair in Molecular Imaging of Diabetes and professor and endocrinologist-lipidologist in the Department of Medicine, Faculty of Medicine at the Université de Sherbrooke. He has been the Scientific Director of the Centre de recherche du CHUS since December 2020. He was the director of the Province of Quebec Research Network on Cardiometabolic Health, Diabetes and Obesity (CMDO Network - https://www.rrcmdo.ca/en/) from 2012-2021 and he is the new scientific co-lead of Diabetes Action Canada (https://diabetesaction.ca/). His research interests include: 1) the role of postprandial fatty acid metabolism in the development of type 2 diabetes and cardiovascular diseases; 2) the investigation of brown adipose tissue metabolism in humans; and 3) the anti-diabetic mechanisms of bariatric surgery. Dr. Carpentier has published more than 178 peer-reviewed manuscript publications cited over 16,000 times (H index 55). He is the recipient of multiple awards, including the 2011 Diabetes Young Investigator Award of the Canadian Society of Endocrinology and Metabolism, the CDA/CIHR Young Investigator Award in 2012, and the Canadian Lipoprotein Conference Physician-Scientist Award in 2014. He has been elected Fellow of the Canadian Academy of Health Sciences (FCAHS, 2015).
Participants should be aware of the following financial/non-financial relationships:
André C. Carpentier MD, FRCPC, CSPQ, FCAHS: Eli Lilly: Grant/Research Support (Ongoing); HLS Therapeutics: Consultant (Ongoing); Janssen: Consultant (Ongoing); Novartis: Consultant (Ongoing); novo nordisk: Consultant (Ongoing); novo nordisk: Grant/Research Support (Ongoing)
Presenting at:
Brown Adipose Tissue - 8:00 AM, November 12th
Dr. Marette received his PhD in physiology from Laval University and then completed a post-doctorat fellowhip at the Hospital for Sick Children and the Faculty of Medicine at the University of Toronto. He is Professor of Medicine and researcher at the Heart and Lung Institute Hospital Center, and at the Institute of Nutrition and Functional Foods at Laval University. He holds a research Chair on the pathogenesis of insulin resistance and cardiovascular diseases (CVD). Dr. Marette is an international renowned expert on the pathogenesis of insulin resistance and cardiometabolic diseases and his research has advanced the understanding of the physiological and molecular mechanisms of inflammation, and opened new possibilities for prevention and treatment and type 2 diabetes and CVD. He is studying how nutrition and food ingredients can modulate the gut microbiota to protect against obesity-linked intestinal inflammation, fatty liver disease and type 2 diabetes. His research is funded by the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC), by the FRQS and FRQNT and the Weston Family and JA De Sève foundations. He is holding a Foundation scheme grant from CIHR and is a member of the Belgium Royal Academy of Medicine. His research work has been published in >300 papers, reviews and book chapters and he was invited to give more than a hundred lectures at various national & international conferences in the last 10 years. He serves as Editor-in-Chief for the Am J Physiol: Endo & Metab. from 2016-2022 and has authored two books in the last few years. Dr. Marette has received several awards for his work including the prestigious Charles Best Award and Lectureship from the University of Toronto for his overall contribution to the advancement of scientific knowledge in the field of diabetes.
Participants should be aware of the following financial/non-financial relationships:
Andre Marette, PhD: Nothing to disclose
Presenting at:
Molecular mechanisms of insulin signalling and resistance in obesity and diabetes - 10:45 AM, Novermber 12th
Anissa is a diabetes researcher, ex-professional hockey player, and soon-to-be dentist. Throughout her hockey career, she played NCAA Division 1, CWHL for the Calgary Inferno and Toronto Furies, and Toronto’s PWHPA division team. As a student-athlete, she obtained her Bachelor of Science from Robert Morris University, majoring in biology with a concentration in Pre-Med, and minoring in chemistry. She went on to complete her Master of Science degree in Experimental Surgery from the University of Alberta, under the supervision of Dr. Shapiro, studying islet cell transplantation. She researched digital therapeutics at UHN ehealth Innovation evaluating telemedicine, human health factors, and implementation science. Today, she is a third-year dental student studying at Western University Schulich School of Medicine and Dentistry, where she also researches diabetes oral health. During her spare time, you can find her outside hiking, biking or camping.
Participants should be aware of the following financial/non-financial relationships:
Anissa Gamble MSc: Nothing to disclose
Presenting at:
Isabel Lockerbie Address: Life's A Gamble - Lessons Learned Living with Diabetes - 9:30 AM, Novermber 12th
Dr. Kramer is an Associate Professor and Clinician-Scientist at the University of Toronto, Division of Endocrinology and Leadership Sinai Centre for Diabetes/Mount Sinai Hospital. Her clinical research work has focused on the pathophysiology and risk factors for the development of type 2 diabetes mellitus (T2DM), particularly the interaction between obesity and T2DM, risk factors for cardiovascular disease in individuals with metabolic abnormalities, and strategies for the treatment of T2DM (including lifestyle interventions and pharmacological approaches). To date, her research has yielded more than 100 original peer-reviewed publications, including first-authorship publications in high-impact general medical journals such as the Annals of Internal Medicine and the British Medical Journal, and top subspecialty journals in the field of diabetes and endocrinology, including Diabetes, Diabetes Care and the Journal of Clinical Endocrinology and Metabolism. She has received a Diabetes Canada (former Canadian Diabetes Association) Clinician Scientist Award (2016-2021), a Banting and Best New Investigator Award 2015/2016, and her research has been funded by the Canadian Institute of Health Research (CIHR) and the Heart and Stroke Foundation of Canada.
Participants should be aware of the following financial/non-financial relationships:
Caroline K. Kramer MD, PhD: Boehringer Ingelheim: Grant/Research Support (Ongoing)
Presenting at:
CanDIP Debate - Medical therapy is more effective than lifestyle therapy in the prevention of diabetes post-GDM - 10:45 AM, Novermber 12th
Dr. Tran is an Assistant Professor and Program Director for the Endocrinology and Metabolism residency training program at the University of Ottawa. He received a Master’s Medical Education degree from the University of Dundee and received the Faculty of Medicine Educator of the Year (Preclerkship) and the 2022 Canadian Association Medical Education Certificate of Merit awards for his contributions to teaching and medical education.
Participants should be aware of the following financial/non-financial relationships:
Christopher Tran MD, MMEd: Nothing to disclose
Presenting at:
Pros/Cons of Pre-Op Steroids for Pituitary Surgery - 10:45 AM, Novermber 12th
Dr. Langlois completed her training in Endocrinology and Metabolism in Sherbrooke and started her career has a clinician and Assistant Professor in Hopital Charles Lemoyne in Longueuil, Quebec, in 2010. Six years later, she pursued a fellowship in neuro-endocrinology with Dr. Maria Fleseriu at Oregon Health and Science University before coming back to Sherbrooke in 2018. She has a clinical interest in pituitary diseases, and she is also an Associate Editor for Frontiers in Endocrinology, as well as a reviewer. She has also contributed to publications on various pituitary diseases.
Participants should be aware of the following financial/non-financial relationships:
Fabienne Langlois MD: Bristol-Myers Squibb: Speaker/Honoraria (Terminated); Novartis: Advisory Board (Terminated); Pfizer: Speaker/Honoraria (Terminated); Recordati Rare Disease: Advisory Board (Terminated); Recordati Rare Disease: Speaker/Honoraria (Terminated)
Presenting at:
Pituitary Session: Treatment Resistant Prolactinomas; Infiltrative Diseases of the Pituitary - 9:30 AM, November 12th
Dr. Steinberg is a Professor of Medicine at McMaster University where he holds a Tier 1 Canada Research Chair and a J. Bruce Duncan Endowed Chair in Metabolic Diseases and is Co-Director of the Centre for Metabolism, Obesity and Diabetes Research. His research studies cellular energy sensing mechanisms and how endocrine factors, lipid metabolism and insulin sensitivity are linked and contribute to the development of obesity, NASH, type 2 diabetes, cardiovascular disease (CVD) and cancer. He has published over 220 papers, many in leading scientific journals (e.g. Nature Medicine, Cell Metabolism, Nature Reviews in Drug Discovery) that have been highly cited (h-index=85). Importantly, many of these studies have laid the foundation for therapies that have recently been approved or are in clinical trials for NASH and CVD. His scientific contributions have been recognized by the Endocrine Society, Diabetes Canada, the Canadian Institutes of Health Research and the American Diabetes Association, who have each presented him with outstanding scientific achievement awards.
Participants should be aware of the following financial/non-financial relationships:
Gregory Steinberg PhD: Esperion Therapeutics: Consultant (Ongoing); Esperion Therapeutics: Grant/Research Support (Ongoing); Espervita Therapeutics: Board Member (Ongoing); Espervita Therapeutics: Grant/Research Support (Ongoing); Espervita Therapeutics: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Espervita Therapeutics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Merck: Advisory Board (Ongoing); Merck: Consultant (Ongoing); Nestle: Grant/Research Support (Ongoing); Nestle: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Novo Nordisk A/S: Grant/Research Support (Ongoing); Novo Nordisk A/S: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Novo Nordisk A/S: Speaker/Honoraria (Ongoing); Poxel Pharmaceuticals: Advisory Board (Ongoing); Poxel Pharmaceuticals: Consultant (Ongoing); Poxel Pharmaceuticals: Grant/Research Support (Ongoing); Poxel Pharmaceuticals: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)
Presenting at:
Brown Adipose Tissue - 8:00 AM, November 12th
Dr. MacKenzie -Feder was trained at McGill University in Medicine and completed her residency at the University of British Columbia in Internal Medicine and Endocrinology and Metabolism. She pursued a research and clinical fellowship in pituitary and adrenal disorders with a special focus on Cushing’s syndrome at the University of Alberta in Edmonton, AB, and at l’Université de Montréal in Montreal, QC. She currently practices general endocrinology and continues to build on her expertise in pituitary and adrenal disorders in Vancouver, BC. She has cross-appointments to St. Paul’s Hospital and Vancouver General Hospital.
Participants should be aware of the following financial/non-financial relationships:
Jessica M. MacKenzie-Feder MDCM: Pfizer: Advisory Board (Terminated); Recordati: Advisory Board (Terminated); Recordati: Speaker/Honoraria (Terminated)
Presenting at:
Pros/Cons of Pre-Op Steroids for Pituitary Surgery - 10:45 AM, Novermber 12th
Originating from Cape Breton, Nova Scotia, Juliana is a Registered Psychologist with the College of Alberta Psychologists working at Springbank Psychology in Calgary, Alberta. Juliana has her Master’s in Special Education from the University of Victoria, along with a Master’s in School and Applied Child Psychology from the University of Calgary. She has many years of experience supporting children, teens and adults. Juliana completes psycho-educational, ADHD, mental health, and gifted assessments. She enjoys placing recommendations that can support learning, growth, self-reflection and well-being for children and their families. Juliana also has been living with type 1 diabetes since she was 10 years old.
Participants should be aware of the following financial/non-financial relationships:
Juliana Walker MEd, MSc: Nothing to disclose
Preseting at:
Diabetes in the Child/Adolescent - 8:00 AM, November 12th
Dr. Booker is a registered psychologist and the director/owner of Springbank Psychology, a private practice in Calgary. Her group has seven psychologists providing assessment and treatment services to young children through adults across a variety of presenting concerns. Dr. Booker specializes in psychoeducational and diagnostic assessments, including significant experience with the assessment of autism spectrum disorders. Dr. Booker completed her doctoral degree in School Psychology at the University of Nebraska-Lincoln. She completed her pre-doctoral internship and post-doctoral fellowship at the Munroe Meyer Institute at the University of Nebraska Medical Center (UNMC), where she worked as a clinical faculty member with the psychology department. While there, she provided clinical services to children and families, taught graduate courses for school psychology and applied behavior analysis, and participated in a variety of research projects in the area of integrating behavioral health in primary care. Dr. Booker was also the director of the post-doctoral fellowship training program at UNMC during her time there as faculty, and she also provided training for the family medicine residency program, prior to moving to Calgary in 2017.
Participants should be aware of the following financial/non-financial relationships:
Lindsay Booker PhD: Springbank Psychology: Employment (Ongoing); Springbank Psychology: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Preseting at:
Diabetes in the Child/Adolescent - 8:00 AM, November 12th
Dr. Lipscombe is a Professor in the Faculty of Medicine and Dalla Lana School of Public Health at the University of Toronto, as well as an Endocrinologist and Clinician Scientist at Women’s College Hospital. Dr. Lipscombe leads a successful internationally recognized research program in diabetes epidemiology and health services, with a particular focus on the burden of diabetes in women. She has published over 100 peer-reviewed articles and led numerous research grants. She has also held several awards, including a Diabetes Investigator Award from Diabetes Canada, where she currently serves on the Board of Directors. Dr. Lipscombe was recently appointed as the inaugural Director for the University of Toronto’s Novo Nordisk Network for Healthy Populations, which is a cross-disciplinary research network to address the burden of diabetes and other chronic diseases through better care, lower risk factors, and healthier living conditions.
Participants should be aware of the following financial/non-financial relationships:
Lorraine Lipscombe MD MSc: novo nordisk: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)
Presenting at:
CanDIP Debate - Medical therapy is more effective than lifestyle therapy in the prevention of diabetes post-GDM - 10:45 AM, Novermber 12th
Joanne Lewis is a registered dietitian and Director of Healthcare Provider Education and Engagement at Diabetes Canada where she has worked for more than seven years to help Canadians receive the best information possible. She is involved in developing resources and programs related to diabetes care and management, as well as the dissemination of the Diabetes Canada Clinical Practice Guidelines. Joanne has several years’ experience practising as a registered dietitian in diabetes clinical settings where she worked closely with patients and their families in managing their diabetes.
